**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 61863

**Manuscript Type:** SYSTEMATIC REVIEWS

**Laparoscopic liver resection for colorectal liver metastases — short- and long-term outcomes: A systematic review**

Taillieu E *et al*. Systematic review: Outcomes of LLR for CRLM

Emily Taillieu, Celine De Meyere, Frederiek Nuytens, Chris Verslype, Mathieu D'Hondt

**Emily Taillieu, Celine De Meyere, Frederiek Nuytens, Mathieu D'Hondt,** Department of Digestive and Hepatobiliary/Pancreatic Surgery, AZ Groeninge, Kortrijk 8500, Belgium

**Chris Verslype,** Department of Gastroenterology and Hepatology, KU Leuven, Leuven 3000, Belgium

**Author contributions:** Taillieu E Performed the research, acquired the data, analyzed the data, wrote the paper; De Meyere C and Nuytens F supervised the paper; Verslype C and D’Hondt M designed the research, supervised the paper.

**Corresponding author: Mathieu D'Hondt, MD, Doctor,** Department of Digestive and Hepatobiliary/Pancreatic Surgery, AZ Groeninge, President Kennedylaan 4, Kortrijk 8500, Belgium. mathieudhondt2000@yahoo.com

**Received:** January 4, 2021

**Revised:** May 16, 2021

**Accepted:** June 25, 2021

**Published online:** July 15, 2021

**Abstract**

BACKGROUND

For well-selected patients and procedures, laparoscopic liver resection (LLR) has become the gold standard for the treatment of colorectal liver metastases (CRLM) when performed in specialized centers. However, little is currently known concerning patient-related and peri-operative factors that could play a role in survival outcomes associated with LLR for CRLM.

AIM

To provide an extensive summary of reported outcomes and prognostic factors associated with LLR for CRLM.

METHODS

A systematic search was performed in PubMed, Embase, Web of Science and the Cochrane Library using the keywords “colorectal liver metastases”, “laparoscopy”, “liver resection”, “prognostic factors”, “outcomes” and “survival”. Only publications written in English and published until December 2019 were included. Furthermore, abstracts of which no accompanying full text was published, reviews, case reports, letters, protocols, comments, surveys and animal studies were excluded. All search results were saved to Endnote Online and imported in Rayyan for systematic selection. Data of interest were extracted from the included publications and tabulated for qualitative analysis.

RESULTS

Out of 1064 articles retrieved by means of a systematic and grey literature search, 77 were included for qualitative analysis. Seventy-two research papers provided data concerning outcomes of LLR for CRLM. Fourteen papers were eligible for extraction of data concerning prognostic factors affecting survival outcomes. Qualitative analysis of the collected data showed that LLR for CRLM is safe, feasible and provides oncological efficiency. Multiple research groups have reported on the short-term advantages of LLR compared to open procedures. The obtained results accounted for minor LLR, as well as major LLR, simultaneous laparoscopic colorectal and liver resection, LLR of posterosuperior segments, two-stage hepatectomy and repeat LLR for CRLM. Few research groups so far have studied prognostic factors affecting long-term outcomes of LLR for CRLM.

CONCLUSION

In experienced hands, LLR for CRLM provides good short- and long-term outcomes, independent of the complexity of the procedure.

**Key Words:** Laparoscopic liver resection; Colorectal liver metastases; Outcomes; Prognostic factors; Systematic review

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Taillieu E, De Meyere C, Nuytens F, Verslype C, D'Hondt M. Laparoscopic liver resection for colorectal liver metastases — short- and long-term outcomes: A systematic review. *World J Gastrointest Oncol* 2021; 13(7): 732-757

**URL:** https://www.wjgnet.com/1948-5204/full/v13/i7/732.htm

**DOI:** https://dx.doi.org/10.4251/wjgo.v13.i7. 732

**Core Tip:** Laparoscopic liver surgery has been widely adopted over the last few years. Meanwhile, laparoscopic liver resection (LLR) has become the gold standard for the treatment of colorectal liver metastases (CRLM) in specialized centers and for well-selected patients and procedures. However, little is known concerning patient-related and peri-operative factors potentially playing a role in survival outcomes associated with LLR for CRLM. The aim of this systematic review is to provide an extensive summary of reported outcomes and prognostic factors associated with LLR for CRLM.

**INTRODUCTION**

Colorectal cancer (CRC) is the third most common malignancy in terms of incidence worldwide and the fourth most common cause of cancer death[1,2]. The most frequent cause of death in CRC patients is metastatic disease[3,4], with the liver being the most common site of metastasis[2,3]. The risk for these patients to develop colorectal liver metastases (CRLM) is up to 50%[2,4-7]. A liver resection (LR) in this context is the only treatment option that can provide a potential cure[2,4,5], with reported 5-year survival rates that vary between 35% and 60%[8]. Despite a high rate of irresectability at initial presentation, advances in the field of liver surgery and the emergence of multidisciplinary approaches in the last couple of decades have led to significant improvements in long-term outcome[5].

Many studies that have been published lately have attempted to elucidate the safety and feasibility of laparoscopic liver resection (LLR) for CRLM, along with its role in the treatment sequence of these patients. Most often, these reports have compared outcomes between LLR and open liver resection (OLR). Randomized controlled trials (RCT) and meta-analyses have shown equal or better short-term outcomes after LLR compared to OLR along with equivalent oncologic outcomes[8-19]. One of these meta-analyses of propensity-score matched studies and RCTs unexpectedly showed a survival advantage favoring LLR over OLR when indicated for CRLM[13]. Little is known however concerning patient-related and peri-operative factors that could play a role in survival outcomes after LLR for CRLM and how these variables in turn could be applied as prognostic factors. As such, for this systematic review, all currently available literature was screened for articles that reported on short- and long-term outcomes following LLR for CRLM along with studies that have analyzed potential prognostic factors (demographics, pre-, intra- and postoperative factors) affecting survival outcomes after LLR for CRLM.

**MATERIALS AND METHODS**

This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist of 2009[20].

***Search strategy***

A systematic search was performed in PubMed, Embase, Web of Science and the Cochrane Library from inception until December 24, 2019 (which was the start date of the performance of the search strategy). The search strategy consisted of breaking up the research question “short- and long-term outcomes following laparoscopic liver resection for colorectal liver metastases and prognostic factors” into separate concepts that fit the PICO (Patient-Intervention-Comparison-Outcome) model: “Colorectal liver metastases” for Patient, “laparoscopy” and “liver resection” for Intervention and “prognostic factors, outcomes and survival” for Outcome. Within the context of this systematic review, “Comparison” was not applicable in the PICO-model. In PubMed, the most appropriate medical subject headings (MeSH) terms were chosen, including "Laparoscopy" AND "Hepatectomy" AND "Colorectal Neoplasms" AND "Prognosis" OR "Survival" OR "Outcome Assessment (Health Care)" OR "Treatment Outcome". The MeSH terms were searched for within the title and the abstract, as were all the corresponding synonyms. The same strategy was applied in Embase by means of Emtree terms, including 'laparoscopy' AND 'liver resection' AND 'colorectal liver metastasis' AND 'prognosis' OR 'survival' OR 'outcome assessment' OR 'treatment outcome' OR 'short term outcome' OR 'long term outcome'. The Emtree terms and the corresponding synonyms were searched for within the title, abstract and keywords. The terms included in both search strategies were aligned to obtain as many results as possible in both databases. The final, aligned search strategy was adopted for the Web of Science database and the Cochrane Library database.

***Inclusion criteria***

For the collection of outcome data: (1) Publications needed to report the result of at least one short- or long-term outcome following LLR; (2) the indication for resection had to be CRLM; and (3) a study cohort of at least 20 patients undergoing LLR needed to be included (to ensure reliability of the studies).

For the collection of data on prognostic factors: (1) Publications needed to report at least one factor (demographic/preoperative/intraoperative/postoperative) to be studied for correlation with a (or multiple) survival outcome(s) of (L)LR together with the associated correlation; (2) the indication for resection had to be CRLM; and (3) a study cohort of at least 20 patients needed to be included (again to ensure reliability of the studies).

In case of multiple studies providing duplicated or the same data, only the most recent study was included. Furthermore, only publications written in English were included.

Abstracts of which no accompanying full text was published, reviews, case reports, letters, protocols, comments, surveys, animal studies, outcome studies that only described treatment procedures other than pure LLR (*e.g.,* chemotherapy regimens, ablation techniques, hand-assisted LLR, robotic LLR) and studies that only described pathologies other than CRLM (*e.g.,* non-colorectal liver metastases) were excluded.

The in- and exclusion criteria were based on those found in already existing literature[18,21,22].

***Selection of search results***

All of the search results were saved to Endnote Online and imported into Rayyan, a web and mobile app for systematic reviews[23]. Deduplication of the search results was first done automatically in Endnote Online and was followed by further manual deduplication in Rayyan. The remaining articles were first screened based on title and abstract according to the presupposed in- and exclusion criteria. An informal grey literature search was performed, and these articles were also subjected to screening of the title and abstract. Thereafter, a full-text analysis was performed until all included articles only contained relevant studies.

***Data extraction***

After full-text analysis, the data relevant for this research were tabulated. This was done separately for research concerning outcomes and research concerning prognostic factors.

For research concerning outcomes, as much of the following data as possible (depending on the data examined in a particular study) were extracted and tabulated for analysis: Study data (title, first author, year of publication, country, study design, number of patients who underwent LLR), patient demographic data (age and sex), intraoperative data (conversion rate, rate of major hepatectomies, operative time, blood loss, operative death and rate of need for blood transfusion), postoperative short-term outcomes (30 d mortality, 30 d morbidity, duration of hospital stay, length of stay at high-dependency unit or intensive care unit, overall rate of postoperative complications, rate of major postoperative complications, rate of need for postoperative blood transfusion, 90 d mortality and time to chemotherapy), characteristics of lesions and resection margins (rates of 1/2/≥ 3 Lesions/specimen, number of lesions, diameter of lesions, size of largest lesion, R1 and R0 resection rates and tumor free resection margin), long-term outcomes (follow-up (FU) duration, recurrence rate, rate of deaths during FU, median/mean survival, 1-, 2-, 3-, 4-, 5-, 7- and 10-year overall survival (OS), disease free survival (DFS) and recurrence free survival (RFS), median DFS and median RFS) and general conclusions about safety, feasibility, effectivity and oncological efficiency. When articles reported data of LLR for CRLM in a specific context (major/minor hepatectomy, LLR of posterosuperior segments, parenchyma sparing LLR, simultaneous laparoscopic colorectal and liver resection, two-stage hepatectomy (TSH) or repeat LLR), outcomes were collected in a subgroup to easily analyze those data within the particular context.

For research concerning prognostic factors, the following data were extracted and tabulated for analysis: Study data (title, first author, year of publication, country, study design, number of patients included, whether or not the study is specific for LLR), patient demographic data (age and sex), the prognostic factor(s), the corresponding correlate(s), and the associated relationship.

In case of propensity score-matched studies, a decision was made to collect data either from the cohort before or after matching in function of which cohort represented more relevant data. In case of stratification, *e.g.,* based on a cut-off at a certain age or a certain tumor size, where the stratification was reported to make no difference in any outcome, and where the general data of the whole cohort was provided, it was decided to collect the reported data of the whole cohort. Otherwise, data were collected of the most relevant group of which the most relevant data were reported. All texts, tables and figures of relevance were reviewed for data extraction.

***Data presentation and analysis***

After data collection, a selection was made of the gathered outcomes based on relevance and the number of times they were reported. The selected outcomes were comprised in tables in which all data of the included articles were tabulated. These tables were analyzed merely qualitatively and discussed in general. Incoherent data or data that seemed to deviate from the other reports were verified in the original article to check for any specific causes explaining the deviation.

**RESULTS**

***Publication selection and characteristics***

Application of the aforementioned search strategy in PubMed, EMBASE, Web of Science and the Cochrane Library resulted in 1061 publications. After deduplication, there were 673 publications left for screening. After screening based on title and abstract, 173 articles were withheld. An informal grey literature search yielded another 3 articles of which the title and abstract seemed to possibly meet the in- and exclusion criteria. All full-text articles were obtained and screened thoroughly for eligibility (based on in- and exclusion criteria), after which extensive data extraction was performed. Reasons to exclude publications during full-text analysis were: Only an abstract was available, outcome studies did not provide any CRLM data or LLR data, outcome studies did not report any of the selected relevant outcomes, studies reported risk factors affecting outcomes that were not prognostic factors, the study cohort consisted of less than 20 patients or no English text was available. This led to a final total of 77 publications for inclusion in the review, and thus, for data extraction. Figure 1 provides a summary of the publication selection process. Tables 1 and 2 provide an overview of the study details of the included studies for data concerning outcomes and prognostic factors, respectively.

***Operative outcomes***

An overview of all extracted operative data can be found in table 3.

For LLR in general, the reported median and mean blood loss volume varied between 50 mL and 400 mL. Median and mean values of operative time varied between 120 and 377 min. High variations in blood loss, ranging from almost no blood loss to 3 L or more, were reported by several authors[24-28]. As stated by Abu Hilal *et al*[24], major hepatectomy was frequently associated with higher blood loss, as well as increased conversion rates, operative times and length of stay. These findings are in line with other data included in the table 3. Greater variations in blood loss (negligible to more than 2 L) were usually associated with greater variations in operative time (less than 60 min to more than 480 min)[24-31]. Correlated with an increased rate of major resection (40% or higher), greater variations were reported in blood loss, operative time[27,29,31], intraoperative transfusion rates (10%-16%)[27,31,32], as well as conversion rates (approximately 10%)[29,32].

Similar conclusions could be drawn when considering data reported about major LLRs specifically. Compared to LLR in general, major LLRs were marked by a higher median blood loss and operative time, as well as an increased variation in blood loss, operative time, intraoperative transfusion rates as well as conversion rates. These differences were even more distinct when compared to minor LLR only. We observed that variations in blood loss and operative time were also higher when considering LLR of the posterosuperior segments.

Data on parenchyma sparing LLR also illustrated a wide variation in blood loss. In the report by Montalti *et al*[33], besides great variation in blood loss (0-2800 mL), a rather high conversion rate of 14.9% was noted, which, according to the authors, was impacted by the amount of blood loss during LLR. Moreover, it was reported that the rate of R1 resections also correlated with the amount of blood loss. However, major LLRs were characterized by high R0 resection rates although blood loss in this specific subset seemed to be higher compared to parenchyma sparing LLR.

In simultaneous laparoscopic colorectal and liver resection, reported blood loss was low. Median and mean values ranged from 175 to 350 mL with the upper limits of variation being much lower than in major LLRs. Concerning operative times, the median and mean values ranged from 206 to 420 minutes, along with upper limits of variation that were frequently higher than in major LLRs. Both Shin *et al*[34] and Xu *et al*[35] reported higher transfusion rates (13.8% and 20%, respectively), which could again be explained by a large proportion of major hepatectomies (29.4% and 20%, respectively).

One included study provided data on TSH. Blood loss, operative times, intraoperative transfusion rates and conversion rates were higher in second stage hepatectomies (SSH) when compared to first stage hepatectomies (FSH). However, the numbers were not exceptionally high.

In repeat LLRs, blood loss and operative times did not differ from primary LLRs. Nomi *et al*[36] reported lower transfusion and conversion rates, while Hallet *et al*[37] reported higher transfusion rates and van der Poel *et al*[38] reported higher conversion rates compared to average primary LLRs. Again this could be due to higher major LLR proportions reported by Hallet *et al*[37] and van der Poel *et al*[38].

No striking differences were noted between data from studies that included patients with a high (> 70 years)[30,39,40] or low (< 55 years)[41,42] median age.

The R0 resection rate was found to be ≥ 90% in 20 out of 32 studies (62.5%) that reported on this topic. In only 7 studies, the R0 resection rate was lower than 85%[37,39,43-47]. Beard *et al*[43] stated that the lower R0 resection rate in their study could be due to the long inclusion period of 15 years. A similar argumentation was found in the reports by de'Angelis *et al*[44], Yue *et al*[39] and Aghayan *et al*[47], which comprised an inclusion period of 13, 17 and 19 years, respectively. Other explanations were not provided.

***Postoperative short-term outcomes***

All extracted postoperative short-term data are listed in table 4.

When considering LLR in general and specific types of LLR, median and mean values of hospital stay ranged from 2.2 to 12 d.

Twenty-eight research groups reported on postoperative morbidity, out of which 25 (89%) mentioned that morbidity occurred in at least 10% of the cases. More than half of these 28 research groups (64%) reported morbidity rates of at least 15%. Sixteen research groups reported on both morbidity rates and major complication rates. These 16 reports indicated that, in many cases, approximately half of the complications were major complications[27,43,45,48,49], and otherwise, the proportion of major complications to all postoperative complications was less than half or nil[30,39,46,50-56]. Nomi *et al*[27] reported very high morbidity and major complication rates of 41.7% and 17.5%, respectively. Besides a long inclusion period of 13 years, no other clear explanation could be identified.

In major LLR, morbidity rates reported by Nomi *et al*[57] and Topal *et al*[58] were higher compared to LLR in general (50.5% and 35%, respectively). Overall, reported morbidity rates and major complication rates for LLR of posterosuperior segments, parenchyma sparing LLR, and simultaneous LLR were in line with those reported for LLR in general. Nomi *et al*[36] mentioned that second or third LLRs carry an increased risk for complications due to intra-abdominal adhesions, variations in liver anatomy in the hypertrophied liver remnant and the possibility of chemotherapy-induced liver injury. However, the authors reported similar morbidity rates for both repeat LLR and primary LLR, thereby confirming the feasibility and safety of second and third LLR. Okumura *et al*[59] reported similar findings in TSH, with slightly higher morbidity and major complication rates after SSH compared to FSH.

Based on the extracted data, the overall reported 90 d postoperative mortality (POM) rates were very low, even when considering specific types of LLR. The highest reported 90 d POM for LLR in general was 2.3%[60]. In studies concerning major LLR, LLR of posterosuperior segments and parenchyma sparing LLR specifically, no 90 d POM occurred. Tranchart *et al*[61] and Okumura *et al*[59] reported a slightly higher 90 d mortality rate in simultaneous laparoscopic colorectal and liver resection (6%) and after SSH (3%), respectively, without any clear explanation being provided.

The time interval between LLR and adjuvant chemotherapy (AC) was only reported by 2 research groups. For LLR in general, Tohme *et al*[55] reported a median interval of 42 d [interquartile range (IQR): 34-54 d]. Okumura *et al*[59] reported a median interval of 1.4 mo (range: 0.9-3.5 mo) after TSH.

***Long-term postoperative outcomes***

An overview of all extracted long-term postoperative data is demonstrated in table 5.

When considering LLR in general along with the specific types of LLR, 1-year OS rates ranged from 84% to 100%, with 18 out of 21 research groups (86%) reporting 1-year OS rates of ≥ 90%. The reported 3-year and 5-year OS rates for LLR in general were marked by some variation, ranging from 64% to 95% and from 42% to 88%, respectively.

The reported DFS rates for LLR in general at 1, 3 and 5 years ranged from 55.7% to 75%, 14% to 69.1% and 14% to 45%, respectively. Remarkably, 3- and 5-year DFS rates reported by the same research groups were often the same or differed only slightly.

For LLR in general, RFS rates ranged from 44% to 71%, 24% to 54.5% and 24% to 53.4% at 1, 3 and 5 years, respectively. Again, it was observed that 3- and 5-year RFS rates reported by the same research group were equal or comparable. RFS rates for LLR of posterosuperior segments were similar to those for LLR in general. Martínez-Cecilia *et al*[62] reported improved RFS rates for parenchyma sparing LLR.

The reported 5-year OS and DFS rates after major LLR (48% and 43%, respectively)[58] were much lower compared to minor LLR (82.1% and 63.2%)[63], indicating worse long-term and oncologic outcome after major LLR. The 5-year DFS for minor LLR was 63.2% on the contrary, which was higher compared to LLR in general, indicating a better oncologic outcome.

In simultaneous laparoscopic colorectal and liver resection, the 1-year DFS rate was reported to be higher (79% and 85.6%) compared to LLR in general[61,64]. Accordingly, 3- and 5-year DFS rates after simultaneous LLR were also higher compared to LLR in general, which suggests that simultaneous LLR seems to provide equal or better long-term and oncologic outcomes compared to other general LLR procedures.

Long-term outcomes did not seem to be particularly compromised when reported R0 resection rates were lower[37,39,43-47].

Studies in which the median or mean FU for recurrence after LLR in general exceeded 24 mo, recurrence rates ranged from 37.8% to 67.7%. When FU was shorter, recurrence rates of 16% to 72% were also reported. Recurrence rates after major LLR and parenchyma sparing LLR were similar, ranging from 57.9% to 67.7%, regardless of the median or mean duration of FU (shorter or longer than 24 mo). Recurrence rates after simultaneous LLR seemed to be somewhat lower, with 3 research groups reporting recurrence rates of 28%, 28.2% and 36%[61,64,65], with a median and mean FU exceeding 24 mo. These findings were in line with the higher DFS rates associated with simultaneous LLR as mentioned earlier. After repeat LLR, reported recurrence rates were found to be higher, ranging from 77.8% to 66.7%[36,37].

***General conclusions reported about LLR for CRLM***

The reported general conclusions per included paper can be found in table 6.

There was not a single paper with a negative conclusion on safety, feasibility, effectiveness or oncological efficiency of LLR for CRLM. It was striking that in 26 out of 31 (84%) papers that reported on LLR in general, it was mentioned that the oncological efficiency was certainly not compromised by this approach. Also, in studies that had discussed minor and parenchyma sparing LLR, as well as in most papers concerning major and simultaneous LLR, a similar message regarding oncological efficiency was reported. Safety, feasibility and short-term advantages of LLR for CRLM were reported for LLR in general, LLR of posterosuperior segments, parenchyma sparing, major, simultaneous, two-stage and repeat LLR. The mentioned short-term advantages often included reduced intraoperative blood loss, a lower morbidity rate, less pain, shorter hospital stay and sometimes shorter operative time.

***Prognostic factors***

An overview of studies that reported on prognostic factors associated with LLR along with their corresponding correlates and associations is shown in table 7.

Fourteen papers were identified which studied prognostic factors specific to LR for CRLM, including 7 (50%) exclusively for LLR for CRLM. Papers that focused on LLR specifically identified the following prognostic factors that were associated with a worse OS: Synchronous CRLM, positive surgical margins, age > 70 years, disease recurrence, a disease-free interval < 12 mo, resection of ≥ 3 metastases, carcinoembryonic antigen (CEA) levels > 10 µg/L, right colonic neoplasms, T-stage of the primary CRC ≥ T3, RAS mutation, clinical risk score, and/or absence of perioperative chemotherapy. Node-positive primary CRC, extrahepatic disease, R1 resection, a disease-free interval < 12 mo, CEA levels > 5 µg/L, lesions located in the posterosuperior segments, blood loss > 1000 mL, a CRLM minimum size < 9 mm, right colonic neoplasms, T-stage of the primary CRC ≥ T3 or T4, RAS mutation, clinical risk score and/or absence of perioperative chemotherapy were associated with worse recurrence, DFS or RFS.

**DISCUSSION**

Previously published systematic reviews and meta-analyses concerning LLR, have frequently discussed a set of heterogeneous groups, that besides CRLM often contain lesions from another histopathological origin, such as hepatocellular carcinoma, non-colorectal liver metastases and other malignancies[66]. Furthermore, no systematic review or meta-analysis has focused so far on potential prognostic factors of survival after LLR for CRLM specifically. In light of these facts, our aim was to provide a systematic review that specifically addressed the role of LLR for CRLM along with all relevant outcomes and prognostic factors associated. We therefore reviewed as much of the existing evidence concerning the subject to date with as few limitations as possible to make the overview as comprehensive as possible.

In 2015, Tian *et al*[8] published a meta-analysis comparing LLR *vs* OLR for CRLM. Since the majority of the articles included for the quantitative analysis of the meta-analysis were also included in the current systematic review, it is no surprise that our results are in line with those reported by Tian *et al*[8]*.* In their meta-analysis, it was found that the results of blood loss, perioperative blood transfusion, postoperative morbidity and mortality, hospitalization time, recurrence, DFS, and OS were in favor of LLR. LLR was, however, not associated with any statistical benefit regarding R0 surgical margins or operative time. In 2012, a meta-analysis on survival and prognostic factors associated with LR in metastatic CRC was published by Kanas *et al*[67]. Node positive primary CRC, CEA level, extrahepatic disease, poor tumor grade, positive surgical margins, multiple CRLM, and tumor diameter > 3 cm were identified as prognostic factors for survival, all with a modest, but significant, predictive relationship. Again, these findings are in line with the reported outcomes included in this systematic review.

A major variability of morbidity rates was observed in function of the research papers included in this study. Morbidity following LLR for CRLM is certainly still present and still needs attention. However, major complication rates are low.

Together with the implementation of LLR for CRLM in the early 2000s, concerns arose about the safety a feasibility of this technique to obtain rates of R0 resection margins and subsequent oncological efficiency similar to those reported after OLR for CRLM. The results of this systematic review appear to refute these concerns, since the vast majority of research groups provide a high rate of R0 resection and oncological efficiency in their reports.

Although no clear correlation between the year of publication and study outcome could be noted, some reported results seem to be influenced by long inclusion periods during which data were collected.

The optimal time interval between LR and AC is defined as 8 wk or less[55,68,69]. Since the reported median intervals were 42 d (IQR: 34-54 d) and 1.4 mo (range: 0.9-3.5 mo), LLR seems to provide the ability to initiate AC within a time frame that results in an optimal treatment sequence.

Concerning oncologic outcomes, the reported 1-, 3- and 5-year OS and DFS rates are comparable to those achieved in a recent RCT by Robles-Campos *et al*[49], indicating that LLR for CRLM offers adequate oncological efficiency in most centers today. As reported by Tabchouri *et al*[70] in 2018, among others, the risk for disease recurrence after LLR for CRLM is high. As illustrated by their results, the probability of recurrence is highest within 24 mo after the initial hepatectomy and diminishes after this point in time. This could underlie the fact that 3-year DFS and RFS rates remain stable with comparable corresponding 5-year DFS and RFS rates.

Some limitations of this systematic review should be taken into account. First, research papers often included several types of LLR besides pure LLR, such as hand-assisted and robotic LLR. Second, the studies included were performed in both high- and low-volume centers. Third, the definitions of postoperative outcomes were not uniform among the included research papers. Fourth, the definition of hospital stay differed among the included papers, with some research groups speaking of an entire hospital stay and others speaking of a postoperative hospital stay. Last, several research groups did not report on the applied definition of major postoperative complications; however, a Clavien-Dindo grade ≥ 3 was most commonly reported.

This review emphasizes the absolute need for future prospective multicenter RCTs. Robust evidence of the short- and long-term benefits of LLR is needed in order to support the increased use of LLR for CRLM compared to OLR reported by many centers.

**CONCLUSION**

LLR is defined as a safe and feasible surgical technique in the treatment of CRLM and associated with satisfactory oncological efficiency. Many research groups report short-term advantages compared to OLR, including reduced intraoperative blood loss, a lower morbidity rate, less pain, shorter hospital stay, and a shorter operative time in selected reports. These conclusions are not compromised when taking into account different subtypes of LLR for CRLM, such as major LLR, simultaneous LLR, LLR for posterosuperior segments, TSH, and repeat LLR. Since few reports so far have studied potential prognostic factors affecting long-term outcomes after LLR for CRLM, future research concerning this topic is needed.

**ARTICLE HIGHLIGHTS**

***Research background***

Laparoscopic liver resection (LLR) for colorectal liver metastases (CRLM) has become the gold standard in specialized centers and for well-selected patients and procedures.

***Research motivation***

Little is known concerning patient-related and peri-operative factors that could play a role in survival outcomes associated with LLR for CRLM.

***Research objectives***

The main objective was to provide an extensive summary of reported outcomes and prognostic factors associated with LLR for CRLM.

***Research methods***

A systematic review was performed in PubMed, EMBASE, Web of Science and the Cochrane Library, after which thorough screening was performed and data was extracted for qualitative analysis.

***Research results***

Qualitative analysis of 77 full-text publications shows that LLR for CRLM is safe, feasible and provides oncological efficiency. This is true for more complex laparoscopic procedures as well. Results on prognostic factors affecting long-term outcomes for LLR for CRLM are scarce.

***Research conclusions***

Besides short-term benefits, satisfactory oncological efficiency is reported for LLR for CRLM.

***Research perspectives***

Little is still known about prognostic factors affecting long-term outcomes of LLR for CRLM, and future prospective multicenter randomized controlled trials are needed to provide robust evidence.

**REFERENCES**

1 **Arnold M**, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. *Gut* 2017; **66**: 683-691 [PMID: 26818619 DOI: 10.1136/gutjnl-2015-310912]

2 **Valderrama-Treviño AI**, Barrera-Mera B, Ceballos-Villalva JC, Montalvo-Javé EE. Hepatic Metastasis from Colorectal Cancer. *Euroasian J Hepatogastroenterol* 2017; **7**: 166-175 [PMID: 29201802 DOI: 10.5005/jp-journals-10018-1241]

3 **Lazorthes F**, Navarro F, Ychou M, Delpero JR, Rougier P; ANAES. [Therapeutic management of hepatic metastases from colorectal cancers]. *Gastroenterol Clin Biol* 2003; **27 Spec No 2**: B7 [PMID: 12637870 DOI: 10.1055/s-2005-916282]

4 **Rothbarth J**, van de Velde CJ. Treatment of liver metastases of colorectal cancer. *Ann Oncol* 2005; **16 Suppl 2**: ii144-ii149 [PMID: 15958446 DOI: 10.1093/annonc/mdi702]

5 **Qin X,** Xu J, Zhong Y. Multidisciplinary management of liver metastases in colorectal cancer: Early diagnosis and treatment. Springer Netherlands; 2016 [DOI: 10.1007/978-94-017-7755-1]

6 **Di Fabio F**, Whistance R, Rahman S, Primrose JN, Pearce NW, Abu Hilal M. Exploring the role of laparoscopic surgery in two-stage hepatectomy for bilobar colorectal liver metastases. *J Laparoendosc Adv Surg Tech A* 2012; **22**: 647-650 [PMID: 22823416 DOI: 10.1089/Lap.2012.0163]

7 **Kilburn DJ**, Chiow AK, Lewin J, Kienzle N, Cavallucci DJ, Bryant R, O'Rourke N. Laparoscopic approach to a planned two-stage hepatectomy for bilobar colorectal liver metastases. *ANZ J Surg* 2016; **86**: 811-815 [PMID: 24990234 DOI: 10.1111/ans.12748]

8 **Tian ZQ**, Su XF, Lin ZY, Wu MC, Wei LX, He J. Meta-analysis of laparoscopic *vs* open liver resection for colorectal liver metastases. *Oncotarget* 2016; **7**: 84544-84555 [PMID: 27811369 DOI: 10.18632/oncotarget.13026]

9 **Fretland ÅA**, Dagenborg VJ, Bjørnelv GMW, Kazaryan AM, Kristiansen R, Fagerland MW, Hausken J, Tønnessen TI, Abildgaard A, Barkhatov L, Yaqub S, Røsok BI, Bjørnbeth BA, Andersen MH, Flatmark K, Aas E, Edwin B. Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial. *Ann Surg* 2018; **267**: 199-207 [PMID: 28657937 DOI: 10.1097/SLA.0000000000002353]

10 **Yoshida H**, Taniai N, Yoshioka M, Hirakata A, Kawano Y, Shimizu T, Ueda J, Takata H, Nakamura Y, Mamada Y. Current Status of Laparoscopic Hepatectomy. *J Nippon Med Sch* 2019; **86**: 201-206 [PMID: 31204380 DOI: 10.1272/jnms.JNMS.2019\_86-411]

11 **Zhang XL**, Liu RF, Zhang D, Zhang YS, Wang T. Laparoscopic *vs* open liver resection for colorectal liver metastases: A systematic review and meta-analysis of studies with propensity score-based analysis. *Int J Surg* 2017; **44**: 191-203 [PMID: 28583897 DOI: 10.1016/j.ijsu.2017.05.073]

12 **Fretland AA,** Aghayan D, Edwin B. Long-term survival after laparoscopic *vs* open resection for colorectal liver metastases. *J Clin Oncol* 2019; **37**: LBA3516 [DOI: 10.1200/JCO.2019.37.18\_suppl.LBA3516]

13 **Syn NL,** Kabir T, Koh YX, Tan HL, Wang LZ, Chin BZ, Wee I, Teo JY, Tai BC, Goh BKP. Survival Advantage of Laparoscopic Versus Open Resection For Colorectal Liver Metastases: A Meta-analysis of Individual Patient Data From Randomized Trials and Propensity-score Matched Studies. *Ann Surg* 2020; **272**: 253-265 [PMID: 32675538 DOI: 10.1097/SLA.0000000000003672]

14 **Luo LX**, Yu ZY, Bai YN. Laparoscopic hepatectomy for liver metastases from colorectal cancer: a meta-analysis. *J Laparoendosc Adv Surg Tech A* 2014; **24**: 213-222 [PMID: 24571350 DOI: 10.1089/Lap.2013.0399]

15 **Kalil JA**, Poirier J, Becker B, Van Dam R, Keutgen X, Schadde E. Laparoscopic Parenchymal-Sparing Hepatectomy: the New Maximally Minimal Invasive Surgery of the Liver-a Systematic Review and Meta-Analysis. *J Gastrointest Surg* 2019; **23**: 860-869 [PMID: 30756316 DOI: 10.1007/s11605-019-04128-w]

16 **Ciria R**, Ocaña S, Gomez-Luque I, Cipriani F, Halls M, Fretland ÅA, Okuda Y, Aroori S, Briceño J, Aldrighetti L, Edwin B, Hilal MA. A systematic review and meta-analysis comparing the short- and long-term outcomes for laparoscopic and open liver resections for liver metastases from colorectal cancer. *Surg Endosc* 2020; **34**: 349-360 [PMID: 30989374 DOI: 10.1007/s00464-019-06774-2]

17 **Wei M**, He Y, Wang J, Chen N, Zhou Z, Wang Z. Laparoscopic *vs* open hepatectomy with or without synchronous colectomy for colorectal liver metastasis: a meta-analysis. *PLoS One* 2014; **9**: e87461 [PMID: 24489916 DOI: 10.1371/journal.pone.0087461]

18 **Kasai M**, Cipriani F, Gayet B, Aldrighetti L, Ratti F, Sarmiento JM, Scatton O, Kim KH, Dagher I, Topal B, Primrose J, Nomi T, Fuks D, Abu Hilal M. Laparoscopic *vs* open major hepatectomy: a systematic review and meta-analysis of individual patient data. *Surgery* 2018; **163**: 985-995 [PMID: 29555197 DOI: 10.1016/j.surg.2018.01.020]

19 **Zhou Y**, Xiao Y, Wu L, Li B, Li H. Laparoscopic liver resection as a safe and efficacious alternative to open resection for colorectal liver metastasis: a meta-analysis. *BMC Surg* 2013; **13**: 44 [PMID: 24083369 DOI: 10.1186/1471-2482-13-44]

20 **Moher D**, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; **6**: e1000097 [PMID: 19621072 DOI: 10.1371/journal.pmed.1000097]

21 **Cheng Y**, Zhang L, Li H, Wang L, Huang Y, Wu L, Zhang Y. Laparoscopic *vs* open liver resection for colorectal liver metastases: a systematic review. *J Surg Res* 2017; **220**: 234-246 [PMID: 29180186 DOI: 10.1016/j.jss.2017.05.110]

22 **Moris D**, Tsilimigras DI, Machairas N, Merath K, Cerullo M, Hasemaki N, Prodromidou A, Cloyd JM, Pawlik TM. Laparoscopic synchronous resection of colorectal cancer and liver metastases: A systematic review. *J Surg Oncol* 2019; **119**: 30-39 [PMID: 30481373 DOI: 10.1002/jso.25313]

23 **Ouzzani M**, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. *Syst Rev* 2016; **5**: 210 [PMID: 27919275 DOI: 10.1186/s13643-016-0384-4]

24 **Abu Hilal M**, Di Fabio F, Abu Salameh M, Pearce NW. Oncological efficiency analysis of laparoscopic liver resection for primary and metastatic cancer: a single-center UK experience. *Arch Surg* 2012; **147**: 42-48 [PMID: 22250111 DOI: 10.1001/archsurg.2011.856]

25 **Barkhatov L**, Fretland ÅA, Kazaryan AM, Røsok BI, Brudvik KW, Waage A, Bjørnbeth BA, Sahakyan MA, Edwin B. Validation of clinical risk scores for laparoscopic liver resections of colorectal liver metastases: A 10-year observed follow-up study. *J Surg Oncol* 2016; **114**: 757-763 [PMID: 27471127 DOI: 10.1002/jso.24391]

26 **Kazaryan AM**, Marangos IP, Røsok BI, Rosseland AR, Villanger O, Fosse E, Mathisen O, Edwin B. Laparoscopic resection of colorectal liver metastases: surgical and long-term oncologic outcome. *Ann Surg* 2010; **252**: 1005-1012 [PMID: 21107111 DOI: 10.1097/SLA.0b013e3181f66954]

27 **Nomi T**, Fuks D, Louvet C, Nakajima Y, Gayet B. Outcomes of Laparoscopic Liver Resection for Patients with Large Colorectal Liver Metastases: A Case-Matched Analysis. *World J Surg* 2016; **40**: 1702-1708 [PMID: 27000874 DOI: 10.1007/s00268-016-3467-4]

28 **Postriganova N**, Kazaryan AM, Røsok BI, Fretland Å, Barkhatov L, Edwin B. Margin status after laparoscopic resection of colorectal liver metastases: does a narrow resection margin have an influence on survival and local recurrence? *HPB (Oxford)* 2014; **16**: 822-829 [PMID: 24308605 DOI: 10.1111/hpb.12204]

29 **Cipriani F**, Rawashdeh M, Stanton L, Armstrong T, Takhar A, Pearce NW, Primrose J, Abu Hilal M. Propensity score-based analysis of outcomes of laparoscopic *vs* open liver resection for colorectal metastases. *Br J Surg* 2016; **103**: 1504-1512 [PMID: 27484847 DOI: 10.1002/bjs.10211]

30 **Martínez-Cecilia D**, Cipriani F, Shelat V, Ratti F, Tranchart H, Barkhatov L, Tomassini F, Montalti R, Halls M, Troisi RI, Dagher I, Aldrighetti L, Edwin B, Abu Hilal M. Laparoscopic Versus Open Liver Resection for Colorectal Metastases in Elderly and Octogenarian Patients: A Multicenter Propensity Score Based Analysis of Short- and Long-term Outcomes. *Ann Surg* 2017; **265**: 1192-1200 [PMID: 28151797 DOI: 10.1097/SLA.0000000000002147]

31 **Nguyen KT**, Laurent A, Dagher I, Geller DA, Steel J, Thomas MT, Marvin M, Ravindra KV, Mejia A, Lainas P, Franco D, Cherqui D, Buell JF, Gamblin TC. Minimally invasive liver resection for metastatic colorectal cancer: a multi-institutional, international report of safety, feasibility, and early outcomes. *Ann Surg* 2009; **250**: 842-848 [PMID: 19806058 DOI: 10.1097/SLA.0b013e3181bc789c]

32 **Castaing D**, Vibert E, Ricca L, Azoulay D, Adam R, Gayet B. Oncologic results of laparoscopic *vs* open hepatectomy for colorectal liver metastases in two specialized centers. *Ann Surg* 2009; **250**: 849-855 [PMID: 19801934 DOI: 10.1097/SLA.0b013e3181bcaf63]

33 **Montalti R**, Tomassini F, Laurent S, Smeets P, De Man M, Geboes K, Libbrecht LJ, Troisi RI. Impact of surgical margins on overall and recurrence-free survival in parenchymal-sparing laparoscopic liver resections of colorectal metastases. *Surg Endosc* 2015; **29**: 2736-2747 [PMID: 25427420 DOI: 10.1007/s00464-014-3999-3]

34 **Shin JK**, Kim HC, Lee WY, Yun SH, Cho YB, Huh JW, Park YA, Heo JS, Kim JM. Comparative study of laparoscopic *vs* open technique for simultaneous resection of colorectal cancer and liver metastases with propensity score analysis. *Surg Endosc* 2020; **34**: 4772-4780 [PMID: 31732856 DOI: 10.1007/s00464-019-07253-4]

35 **Xu X**, Guo Y, Chen G, Li C, Wang H, Dong G. Laparoscopic resections of colorectal cancer and synchronous liver metastases: a case controlled study. *Minim Invasive Ther Allied Technol* 2018; **27**: 209-216 [PMID: 28925798 DOI: 10.1080/13645706.2017.1378236]

36 **Nomi T**, Fuks D, Ogiso S, Nakajima Y, Louvet C, Gayet B. Second and Third Laparoscopic Liver Resection for Patients With Recurrent Colorectal Liver Metastases. *Ann Surg* 2016; **263**: e68-e72 [PMID: 26641255 DOI: 10.1097/SLA.0000000000001528]

37 **Hallet J**, Sa Cunha A, Cherqui D, Gayet B, Goéré D, Bachellier P, Laurent A, Fuks D, Navarro F, Pessaux P; French Colorectal Liver Metastases Working Group, Association Française de Chirurgie. Laparoscopic Compared to Open Repeat Hepatectomy for Colorectal Liver Metastases: a Multi-institutional Propensity-Matched Analysis of Short- and Long-Term Outcomes. *World J Surg* 2017; **41**: 3189-3198 [PMID: 28717911 DOI: 10.1007/s00268-017-4119-z]

38 **van der Poel MJ**, Barkhatov L, Fuks D, Berardi G, Cipriani F, Aljaiuossi A, Lainas P, Dagher I, D'Hondt M, Rotellar F, Besselink MG, Aldrighetti L, Troisi RI, Gayet B, Edwin B, Abu Hilal M. Multicentre propensity score-matched study of laparoscopic *vs* open repeat liver resection for colorectal liver metastases. *Br J Surg* 2019; **106**: 783-789 [PMID: 30706451 DOI: 10.1002/bjs.11096]

39 **Yue M**, Li S, Yan G, Li C, Kang Z. Short- and long-term outcomes of laparoscopic hepatectomy for colorectal liver metastases in elderly patients. *Cancer Manag Res* 2018; **10**: 2581-2587 [PMID: 30127644 DOI: 10.2147/cmar.s156379]

40 **Berti S**, Francone E, Minuto M, Bonfante P, Sagnelli C, Bianchi C, Tognoni A, Falco E. Synchronous totally laparoscopic management of colorectal cancer and resectable liver metastases: a single center experience. *Langenbecks Arch Surg* 2015; **400**: 495-503 [PMID: 25681240 DOI: 10.1007/s00423-015-1281-3]

41 **Qiu J**, Chen S, Pankaj P, Wu H. Laparoscopic hepatectomy for hepatic colorectal metastases -- a retrospective comparative cohort analysis and literature review. *PLoS One* 2013; **8**: e60153 [PMID: 23555908 DOI: 10.1371/journal.pone.0060153]

42 **Okuno M**, Goumard C, Mizuno T, Omichi K, Tzeng CD, Chun YS, Aloia TA, Fleming JB, Lee JE, Vauthey JN, Conrad C. Operative and short-term oncologic outcomes of laparoscopic *vs* open liver resection for colorectal liver metastases located in the posterosuperior liver: a propensity score matching analysis. *Surg Endosc* 2018; **32**: 1776-1786 [PMID: 28917012 DOI: 10.1007/s00464-017-5861-x]

43 **Beard RE**, Khan S, Troisi RI, Montalti R, Vanlander A, Fong Y, Kingham TP, Boerner T, Berber E, Kahramangil B, Buell JF, Martinie JB, Vrochides D, Shen C, Molinari M, Geller DA, Tsung A. Long-Term and Oncologic Outcomes of Robotic Versus Laparoscopic Liver Resection for Metastatic Colorectal Cancer: A Multicenter, Propensity Score Matching Analysis. *World J Surg* 2020; **44**: 887-895 [PMID: 31748885 DOI: 10.1007/s00268-019-05270-x]

44 **de'Angelis N**, Eshkenazy R, Brunetti F, Valente R, Costa M, Disabato M, Salloum C, Compagnon P, Laurent A, Azoulay D. Laparoscopic *vs* open resection for colorectal liver metastases: a single-center study with propensity score analysis. *J Laparoendosc Adv Surg Tech A* 2015; **25**: 12-20 [PMID: 25402497 DOI: 10.1089/Lap.2014.0477]

45 **Goumard C**, Nancy You Y, Okuno M, Kutlu O, Chen HC, Simoneau E, Vega EA, Chun YS, David Tzeng C, Eng C, Vauthey JN, Conrad C. Minimally invasive management of the entire treatment sequence in patients with stage IV colorectal cancer: a propensity-score weighting analysis. *HPB (Oxford)* 2018; **20**: 1150-1156 [PMID: 30005993 DOI: 10.1016/j.hpb.2018.05.011]

46 **Karagkounis G**, Akyuz M, Guerron AD, Yazici P, Aucejo FN, Quintini C, Miller CM, Vogt DP, Fung JJ, Berber E. Perioperative and oncologic outcomes of minimally invasive liver resection for colorectal metastases: A case-control study of 130 patients. *Surgery* 2016; **160**: 1097-1103 [PMID: 27486002 DOI: 10.1016/j.surg.2016.04.043]

47 **Aghayan DL**, Pelanis E, Avdem Fretland Å, Kazaryan AM, Sahakyan MA, Røsok BI, Barkhatov L, Bjørnbeth BA, Jakob Elle O, Edwin B. Laparoscopic Parenchyma-sparing Liver Resection for Colorectal Metastases. *Radiol Oncol* 2018; **52**: 36-41 [PMID: 29520204 DOI: 10.1515/raon-2017-0046]

48 **Cheung TT**, Poon RT, Yuen WK, Chok KS, Tsang SH, Yau T, Chan SC, Lo CM. Outcome of laparoscopic *vs* open hepatectomy for colorectal liver metastases. *ANZ J Surg* 2013; **83**: 847-852 [PMID: 23035809 DOI: 10.1111/j.1445-2197.2012.06270.x]

49 **Robles-Campos R**, Lopez-Lopez V, Brusadin R, Lopez-Conesa A, Gil-Vazquez PJ, Navarro-Barrios Á, Parrilla P. Open *vs* minimally invasive liver surgery for colorectal liver metastases (LapOpHuva): a prospective randomized controlled trial. *Surg Endosc* 2019; **33**: 3926-3936 [PMID: 30701365 DOI: 10.1007/s00464-019-06679-0]

50 **Guerron AD**, Aliyev S, Agcaoglu O, Aksoy E, Taskin HE, Aucejo F, Miller C, Fung J, Berber E. Laparoscopic *vs* open resection of colorectal liver metastasis. *Surg Endosc* 2013; **27**: 1138-1143 [PMID: 23052537 DOI: 10.1007/s00464-012-2563-2]

51 **Kubota Y**, Otsuka Y, Tsuchiya M, Katagiri T, Ishii J, Maeda T, Tamura A, Kaneko H. Efficacy of laparoscopic liver resection in colorectal liver metastases and the influence of preoperative chemotherapy. *World J Surg Oncol* 2014; **12**: 351 [PMID: 25416585 DOI: 10.1186/1477-7819-12-351]

52 **Langella S**, Russolillo N, D'Eletto M, Forchino F, Lo Tesoriere R, Ferrero A. Oncological safety of ultrasound-guided laparoscopic liver resection for colorectal metastases: a case-control study. *Updates Surg* 2015; **67**: 147-155 [PMID: 26220046 DOI: 10.1007/s13304-015-0325-0]

53 **Ratti F**, Fiorentini G, Cipriani F, Catena M, Paganelli M, Aldrighetti L. Laparoscopic *vs* Open Surgery for Colorectal Liver Metastases. *JAMA Surg* 2018; **153**: 1028-1035 [PMID: 30027220 DOI: 10.1001/jamasurg.2018.2107]

54 **Shim JR**, Lee SD, Park HM, Lee EC, Park B, Han SS, Kim SH, Park SJ. Outcomes of liver resection in patients with colorectal liver metastases by laparoscopic or open surgery. *Ann Hepatobiliary Pancreat Surg* 2018; **22**: 223-230 [PMID: 30215044 DOI: 10.14701/ahbps.2018.22.3.223]

55 **Tohme S**, Goswami J, Han K, Chidi AP, Geller DA, Reddy S, Gleisner A, Tsung A. Minimally Invasive Resection of Colorectal Cancer Liver Metastases Leads to an Earlier Initiation of Chemotherapy Compared to Open Surgery. *J Gastrointest Surg* 2015; **19**: 2199-2206 [PMID: 26438480 DOI: 10.1007/s11605-015-2962-5]

56 **Zeng Y**, Tian M. Laparoscopic *vs* open hepatectomy for elderly patients with liver metastases from colorectal cancer. *J BUON* 2016; **21**: 1146-1152 [PMID: 27837616]

57 **Nomi T**, Fuks D, Kawaguchi Y, Mal F, Nakajima Y, Gayet B. Laparoscopic major hepatectomy for colorectal liver metastases in elderly patients: a single-center, case-matched study. *Surg Endosc* 2015; **29**: 1368-1375 [PMID: 25149638 DOI: 10.1007/s00464-014-3806-1]

58 **Topal H**, Tiek J, Aerts R, Topal B. Outcome of laparoscopic major liver resection for colorectal metastases. *Surg Endosc* 2012; **26**: 2451-2455 [PMID: 22358126 DOI: 10.1007/s00464-012-2209-4]

59 **Okumura S**, Goumard C, Gayet B, Fuks D, Scatton O. Laparoscopic *vs* open two-stage hepatectomy for bilobar colorectal liver metastases: A bi-institutional, propensity score-matched study. *Surgery* 2019; **166**: 959-966 [PMID: 31395397 DOI: 10.1016/j.surg.2019.06.019]

60 **Allard MA**, Cunha AS, Gayet B, Adam R, Goere D, Bachellier P, Azoulay D, Ayav A, Navarro F, Pessaux P; Colorectal Liver Metastases-French Study Group. Early and Long-term Oncological Outcomes After Laparoscopic Resection for Colorectal Liver Metastases: A Propensity Score-based Analysis. *Ann Surg* 2015; **262**: 794-802 [PMID: 26583668 DOI: 10.1097/sla.0000000000001475]

61 **Tranchart H**, Fuks D, Vigano L, Ferretti S, Paye F, Wakabayashi G, Ferrero A, Gayet B, Dagher I. Laparoscopic simultaneous resection of colorectal primary tumor and liver metastases: a propensity score matching analysis. *Surg Endosc* 2016; **30**: 1853-1862 [PMID: 26275554 DOI: 10.1007/s00464-016-4766-4]

62 **Martínez-Cecilia D**, Fontana M, Siddiqi NN, Halls M, Barbaro S, Abu-Hilal M. Laparoscopic parenchymal sparing resections in segment 8: techniques for a demanding and infrequent procedure. *Surg Endosc* 2018; **32**: 2012-2019 [PMID: 29075968 DOI: 10.1007/s00464-017-5897-y]

63 **Vavra P**, Nowakova J, Ostruszka P, Hasal M, Jurcikova J, Martinek L, Penhaker M, Ihnat P, Habib N, Zonca P. Colorectal cancer liver metastases: laparoscopic and open radiofrequency-assisted surgery. *Wideochir Inne Tech Maloinwazyjne* 2015; **10**: 205-212 [PMID: 26240620 DOI: 10.5114/wiitm.2015.52082]

64 **Ferretti S**, Tranchart H, Buell JF, Eretta C, Patriti A, Spampinato MG, Huh JW, Vigano L, Han HS, Ettorre GM, Jovine E, Gamblin TC, Belli G, Wakabayashi G, Gayet B, Dagher I. Laparoscopic Simultaneous Resection of Colorectal Primary Tumor and Liver Metastases: Results of a Multicenter International Study. *World J Surg* 2015; **39**: 2052-2060 [PMID: 25813824 DOI: 10.1007/s00268-015-3034-4]

65 **Ratti F**, Catena M, Di Palo S, Staudacher C, Aldrighetti L. Impact of totally laparoscopic combined management of colorectal cancer with synchronous hepatic metastases on severity of complications: a propensity-score-based analysis. *Surg Endosc* 2016; **30**: 4934-4945 [PMID: 26944725 DOI: 10.1007/s00464-016-4835-8]

66 **Tranchart H**, Dagher I. Laparoscopic liver resection: a review. *J Visc Surg* 2014; **151**: 107-115 [PMID: 24365035 DOI: 10.1016/j.jviscsurg.2013.10.003]

67 **Kanas GP**, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, Alexander DD, Choti MA, Poston G. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. *Clin Epidemiol* 2012; **4**: 283-301 [PMID: 23152705 DOI: 10.2147/CLEP.S34285]

68 **Kawai T**, Goumard C, Jeune F, Savier E, Vaillant JC, Scatton O. Laparoscopic liver resection for colorectal liver metastasis patients allows patients to start adjuvant chemotherapy without delay: a propensity score analysis. *Surg Endosc* 2018; **32**: 3273-3281 [PMID: 29340819 DOI: 10.1007/s00464-018-6046-y]

69 **Mbah N**, Agle SC, Philips P, Egger ME, Scoggins CR, McMasters KM, Martin RCG. Laparoscopic hepatectomy significantly shortens the time to postoperative chemotherapy in patients undergoing major hepatectomies. *Am J Surg* 2017; **213**: 1060-1064 [PMID: 28173934 DOI: 10.1016/j.amjsurg.2017.01.031]

70 **Tabchouri N**, Gayet B, Okumura S, Donatelli G, Beaussier M, Bennamoun M, Louvet C, Fuks D. Recurrence patterns after laparoscopic resection of colorectal liver metastases. *Surg Endosc* 2018; **32**: 4788-4797 [PMID: 29761279 DOI: 10.1007/s00464-018-6229-6]

71 **Abu Hilal M**, Underwood T, Zuccaro M, Primrose J, Pearce N. Short- and medium-term results of totally laparoscopic resection for colorectal liver metastases. *Br J Surg* 2010; **97**: 927-933 [PMID: 20474003 DOI: 10.1002/bjs.7034]

72 **Beppu T**, Wakabayashi G, Hasegawa K, Gotohda N, Mizuguchi T, Takahashi Y, Hirokawa F, Taniai N, Watanabe M, Katou M, Nagano H, Honda G, Baba H, Kokudo N, Konishi M, Hirata K, Yamamoto M, Uchiyama K, Uchida E, Kusachi S, Kubota K, Mori M, Takahashi K, Kikuchi K, Miyata H, Takahara T, Nakamura M, Kaneko H, Yamaue H, Miyazaki M, Takada T. Long-term and perioperative outcomes of laparoscopic *vs* open liver resection for colorectal liver metastases with propensity score matching: a multi-institutional Japanese study. *J Hepatobiliary Pancreat Sci* 2015; **22**: 711-720 [PMID: 25902703 DOI: 10.1002/jhbp.261]

73 **Berardi G**, Van Cleven S, Fretland ÅA, Barkhatov L, Halls M, Cipriani F, Aldrighetti L, Abu Hilal M, Edwin B, Troisi RI. Evolution of Laparoscopic Liver Surgery from Innovation to Implementation to Mastery: Perioperative and Oncologic Outcomes of 2,238 Patients from 4 European Specialized Centers. *J Am Coll Surg* 2017; **225**: 639-649 [PMID: 28838869 DOI: 10.1016/j.jamcollsurg.2017.08.006]

74 **Chen TH**, Yang HR, Jeng LB, Hsu SC, Hsu CH, Yeh CC, Yang MD, Chen WT. Laparoscopic Liver Resection: Experience of 436 Cases in One Center. *J Gastrointest Surg* 2019; **23**: 1949-1956 [PMID: 30421118 DOI: 10.1007/s11605-018-4023-3]

75 **Cipriani F**, Rawashdeh M, Ahmed M, Armstrong T, Pearce NW, Abu Hilal M. Oncological outcomes of laparoscopic surgery of liver metastases: a single-centre experience. *Updates Surg* 2015; **67**: 185-191 [PMID: 26109140 DOI: 10.1007/s13304-015-0308-1]

76 **D’Hondt M,** Willems E, Parmentier I, Pottel H, Verslype C, De Meyere C, Vansteenkiste F, Besselink M. Short term and oncologic outcomes of the first 250 Laparoscopic liver resections performed by a laparoscopically trained liver surgeon. *HPB* 2018; **20**: S437 [DOI: 10.1016/j.hpb.2018.06.2816]

77 **Efanov M,** Alikhanov R, Tsvirkun V, Kazakov I, Vankovich A, Kim P, Grendal K, Zamanov E. Minimally Invasive *vs* open hepatectomy for colorectal cancer liver metastases: comparative analysis of short-term results and survival with propensity score matching. *HPB* 2018; **20**: S363 [DOI: 10.1016/j.hpb.2018.06.2613]

78 **Eveno C,** Cailliez V, Lopezben S, Mirza DF, Kaiser G, Lapointe R, Mentha G, Pardo F, Adam R, Cherqui D. Role of laparoscopic approach in colorectal liver metastasis. An international multi-center data analysis using liver met survey. *HPB* 2016; **18**: e61-62 [DOI: 10.1016/j.hpb.2016.02.149]

79 **Hirokawa F**, Hayashi M, Miyamoto Y, Asakuma M, Shimizu T, Komeda K, Inoue Y, Uchiyama K. Short- and long-term outcomes of laparoscopic *vs* open hepatectomy for small malignant liver tumors: a single-center experience. *Surg Endosc* 2015; **29**: 458-465 [PMID: 24993176 DOI: 10.1007/s00464-014-3687-3]

80 **Inoue Y**, Hayashi M, Tanaka R, Komeda K, Hirokawa F, Uchiyama K. Short-term results of laparoscopic *vs* open liver resection for liver metastasis from colorectal cancer: a comparative study. *Am Surg* 2013; **79**: 495-501 [PMID: 23635585]

81 **Iwahashi S**, Shimada M, Utsunomiya T, Imura S, Morine Y, Ikemoto T, Arakawa Y, Mori H, Kanamoto M, Yamada S. Laparoscopic hepatic resection for metastatic liver tumor of colorectal cancer: comparative analysis of short- and long-term results. *Surg Endosc* 2014; **28**: 80-84 [PMID: 23996337 DOI: 10.1007/s00464-013-3165-3]

82 **Kasai M**, Van Damme N, Berardi G, Geboes K, Laurent S, Troisi RI. The inflammatory response to stress and angiogenesis in liver resection for colorectal liver metastases: a randomized controlled trial comparing open *vs* laparoscopic approach. *Acta Chir Belg* 2018; **118**: 172-180 [PMID: 29179666 DOI: 10.1080/00015458.2017.1407118]

83 **Kazaryan AM**, Pavlik Marangos I, Rosseland AR, Røsok BI, Mala T, Villanger O, Mathisen O, Giercksky KE, Edwin B. Laparoscopic liver resection for malignant and benign lesions: ten-year Norwegian single-center experience. *Arch Surg* 2010; **145**: 34-40 [PMID: 20083752 DOI: 10.1001/archsurg.2009.229]

84 **Lewin JW**, O'Rourke NA, Chiow AKH, Bryant R, Martin I, Nathanson LK, Cavallucci DJ. Long-term survival in laparoscopic *vs* open resection for colorectal liver metastases: inverse probability of treatment weighting using propensity scores. *HPB (Oxford)* 2016; **18**: 183-191 [PMID: 26902138 DOI: 10.1016/j.hpb.2015.08.001]

85 **Shelat VG**, Cipriani F, Basseres T, Armstrong TH, Takhar AS, Pearce NW, AbuHilal M. Pure laparoscopic liver resection for large malignant tumors: does size matter? *Ann Surg Oncol* 2015; **22**: 1288-1293 [PMID: 25256130 DOI: 10.1245/s10434-014-4107-6]

86 **Topal B**, Tiek J, Fieuws S, Aerts R, Van Cutsem E, Roskams T, Prenen H. Minimally invasive liver surgery for metastases from colorectal cancer: oncologic outcome and prognostic factors. *Surg Endosc* 2012; **26**: 2288-2298 [PMID: 22311303 DOI: 10.1007/s00464-012-2176-9]

87 **Vibert E**, Perniceni T, Levard H, Denet C, Shahri NK, Gayet B. Laparoscopic liver resection. *Br J Surg* 2006; **93**: 67-72 [PMID: 16273531 DOI: 10.1002/bjs.5150]

88 **Kwon IS**, Yun SS, Lee DS, Kim HJ. Laparoscopic liver resection for malignant liver tumors, why not more? *J Korean Surg Soc* 2012; **83**: 30-35 [PMID: 22792531 DOI: 10.4174/jkss.2012.83.1.30]

89 **Cugat Andorrà E**, Herrero Fonollosa E, García Domingo MI, Camps Lasa J, Carvajal López F, Rodríguez Campos A, Cirera Nogueras L, Fernández Plana J, de Marcos Izquierdo JÁ, Paraira Beser M, San Martín Elizaincín M. [Results after laparoscopic liver resection: an appropriate option in malignant disease]. *Cir Esp* 2013; **91**: 510-516 [PMID: 23668943 DOI: 10.1016/j.ciresp.2012.12.007]

90 **Abu Hilal M**, Di Fabio F, Teng MJ, Lykoudis P, Primrose JN, Pearce NW. Single-centre comparative study of laparoscopic *vs* open right hepatectomy. *J Gastrointest Surg* 2011; **15**: 818-823 [PMID: 21380633 DOI: 10.1007/s11605-011-1468-z]

91 **Montalti R**, Scuderi V, Patriti A, Vivarelli M, Troisi RI. Robotic *vs* laparoscopic resections of posterosuperior segments of the liver: a propensity score-matched comparison. *Surg Endosc* 2016; **30**: 1004-1013 [PMID: 26123328 DOI: 10.1007/s00464-015-4284-9]

92 **Portigliotti L**, Fuks D, Slivca O, Bourdeaux C, Nomi T, Bennamoun M, Gentilli S, Gayet B. A comparison of laparoscopic resection of posterior segments with formal laparoscopic right hepatectomy for colorectal liver metastases: a single-institution study. *Surg Endosc* 2017; **31**: 2560-2565 [PMID: 27752815 DOI: 10.1007/s00464-016-5261-7]

93 **Scuderi V**, Barkhatov L, Montalti R, Ratti F, Cipriani F, Pardo F, Tranchart H, Dagher I, Rotellar F, Abu Hilal M, Edwin B, Vivarelli M, Aldrighetti L, Troisi RI. Outcome after laparoscopic and open resections of posterosuperior segments of the liver. *Br J Surg* 2017; **104**: 751-759 [PMID: 28194774 DOI: 10.1002/bjs.10489]

94 **Efanov M**, Granov D, Alikhanov R, Rutkin I, Tsvirkun V, Kazakov I, Vankovich A, Koroleva A, Kovalenko D. Expanding indications for laparoscopic parenchyma-sparing resection of posterosuperior liver segments in patients with colorectal metastases: comparison with open hepatectomy for immediate and long-term outcomes. *Surg Endosc* 2021; **35**: 96-103 [PMID: 31932927 DOI: 10.1007/s00464-019-07363-z]

95 **Okumura S**, Tabchouri N, Leung U, Tinguely P, Louvet C, Beaussier M, Gayet B, Fuks D. Laparoscopic Parenchymal-Sparing Hepatectomy for Multiple Colorectal Liver Metastases Improves Outcomes and Salvageability: A Propensity Score-Matched Analysis. *Ann Surg Oncol* 2019; **26**: 4576-4586 [PMID: 31605335 DOI: 10.1245/s10434-019-07902-x]

96 **Jung KU**, Kim HC, Cho YB, Kwon CH, Yun SH, Heo JS, Lee WY, Chun HK. Outcomes of simultaneous laparoscopic colorectal and hepatic resection for patients with colorectal cancers: a comparative study. *J Laparoendosc Adv Surg Tech A* 2014; **24**: 229-235 [PMID: 24571378 DOI: 10.1089/Lap.2013.0475]

97 **van der Poel MJ**, Tanis PJ, Marsman HA, Rijken AM, Gertsen EC, Ovaere S, Gerhards MF, Besselink MG, D'Hondt M, Gobardhan PD. Laparoscopic combined resection of liver metastases and colorectal cancer: a multicenter, case-matched study using propensity scores. *Surg Endosc* 2019; **33**: 1124-1130 [PMID: 30069639 DOI: 10.1007/s00464-018-6371-1]

98 **Cervantes B,** Gayet B, Frosio F, Tabchouri N, Bennamoun M, Alexandra N, Louvet C, Fuks D. The smallest colorectal liver metastasis size as a prognosis factor after laparoscopic liver resection. *Ann Oncol* 2019; **30**: v213 [DOI: 10.1093/annonc/mdz246.042]

99 **de Haas RJ**, Rahy Martin AC, Wicherts DA, Azoulay D, Castaing D, Adam R. Long-term outcome in patients with adrenal metastases following resection of colorectal liver metastases. *Br J Surg* 2009; **96**: 935-940 [PMID: 19591169 DOI: 10.1002/bjs.6646]

100 **Jones C**, Badger SA, Stevenson M, Diamond T, McKie LD, Taylor MA, Wilson RH, Lynch TB. PET-CT as a predictor of outcome in resectable colorectal liver metastases. *Eur J Gastroenterol Hepatol* 2014; **26**: 466-472 [PMID: 24445726 DOI: 10.1097/MEG.0000000000000036]

101 **Ratti F**, Fuks D, Cipriani F, Gayet B, Aldrighetti L. Timing of Perioperative Chemotherapy Does Not Influence Long-Term Outcome of Patients Undergoing Combined Laparoscopic Colorectal and Liver Resection in Selected Upfront Resectable Synchronous Liver Metastases. *World J Surg* 2019; **43**: 3110-3119 [PMID: 31451846 DOI: 10.1007/s00268-019-05142-4]

102 **Nierop PMH**, Höppener DJ, van der Stok EP, Galjart B, Buisman FE, Balachandran VP, Jarnagin WR, Kingham TP, Allen PJ, Shia J, Vermeulen PB, Groot Koerkamp B, Grünhagen DJ, Verhoef C, D'Angelica MI. Histopathological growth patterns and positive margins after resection of colorectal liver metastases. *HPB (Oxford)* 2020; **22**: 911-919 [PMID: 31735649 DOI: 10.1016/j.hpb.2019.10.015]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** January 4, 2021

**First decision:** May 3, 2021

**Article in press:** June 25, 2021

**Specialty type:** Surgery

**Country/Territory of origin:** Belgium

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Aseni P **S-Editor:** Ma YJ **L-Editor:** Filipodia **P-Editor:** Li JH

**Figure Legends**



**Figure 1** **Flow diagram of the systematic review selection process.** Adapted from Ref.[20].

**Table 1 Study details of studies concerning outcomes**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ref. | year | Country | Study design | Number of patients | Age in yr |
| Abu Hilal *et al*[24] | 2012 | United Kingdom | Retrosp. | 83 | 66 (32-85) |
| Abu Hilal *et al*[71] | 2010 | United Kingdom | Retrosp. | 50 | 66 (17)1 |
| Allard *et al*[60] | 2015 | France | Retrosp., PSM | 176 | 65.1 ± 11 |
| Barkhatov *et al*[25] | 2016 | Norway | Retrosp. | 144 | 69 (30-89) |
| Beard *et al*[43] | 2015 | United States | Retrosp., PSM | 115 | 61 ± 12 |
| Beppu *et al*[72] | 2015 | Japan | Retrosp., PSM | 171 | - |
| Berardi *et al*[73] | 2017 | Belgium, Norway, United Kingdom, Italy | Retrosp. | 1048 | - |
| Castaing *et al*[32] | 2009 | France | Retrosp. | 60 | 62 ± 11 |
| Chen *et al*[74] | 2018 | China | Retrosp. | 156 | - |
| Cheung *et al*[48] | 2013 | China | Retrosp., case-matched control | 20 | 57.5 (42-74) |
| Cipriani *et al*[75] | 2015 | United Kingdom | Retrosp. | 142 | - |
| Cipriani *et al*[29] | 2016 | United Kingdom | Retrosp., PSM | 133 | - |
| D’Hondt *et al*[76] | 2018 | Belgium | Retrosp. | 136 | - |
| de’Angelis *et al*[44] | 2015 | France | Retrosp., PSM | 52 | 63 (32-81) |
| Efanov *et al*[77] | 2018 | Russia | Retrosp., PSM | 60 | - |
| Eveno *et al*[78] | 2016 | France, Spain, United Kingdom, Germany, Canada, Switzerland | Retrosp., PSM | 585 | - |
| Fretland *et al*[12] | 2019 | Norway | RCT | 133 | - |
| Fretland *et al*[9] | 2018 | Norway | RCT | 133 | 67 ± 8 |
| Goumard *et al*[45] | 2018 | United States | Retrosp., PSM | 43 | 59 (26-78) |
| Guerron *et al*[50] | 2013 | United States | Retrosp. | 40 | 66.2 ± 1.9 |
| Hirokawa *et al*[79] | 2014 | United States | Retrosp., matched-pair | 46 | - |
| Inoue *et al*[80] | 2013 | Japan | Retrosp. | 23 | 66.1 ± 9.6 |
| Iwahashi *et al*[81] | 2014 | United States | Retrosp., matched-pair | 21 | 67.5 (47-92) |
| Karagkounis *et al*[46] | 2016 | United States | Retrosp., case-control | 65 | 64 (54-71)1 |
| Kasai *et al*[82] | 2018 | Belgium | RCT | 20 | 65.2 (40.4-86.1) |
| Kazaryan *et al*[26] | 2010 | Norway | Retrosp. | 107 | - |
| Kazaryan *et al*[83] | 2010 | Norway | Retrosp. | 96 | - |
| Kubota *et al*[51] | 2014 | Japan | Retrosp. | 43 | 64.4 ± 11.4 |
| Langella *et al*[52] | 2015 | Italy | Retrosp., case-control | 37 | 63 (37-86) |
| Lewin *et al*[84] | 2016 | Australia | Retrosp., PSM | 146 | - |
| Martínez-Cecilia *et al*[30] | 2017 | United Kingdom, Italy, France, Belgium, Norway | Retrosp., PSM | 225 | 75 (70-87)1 |
| Nguyen *et al*[31] | 2009 | United States, France | Retrosp. | 109 | 63 (32-88) |
| Nomi *et al*[27] | 2016 | France, Japan | Retrosp., case-matched | 120 | 61 (26-89) |
| Postriganova *et al*[28] | 2014 | Norway | Retrosp. | 155 | 66 (35-84) |
| Qiu *et al*[41] | 2013 | China | Retrosp., comparative cohort | 30 | 52.5 ± 11.5 |
| Ratti *et al*[53] | 2018 | Italy | Retrosp., PSM | 104 | 62 (35-81) |
| Robles-Campos *et al*[49] | 2019 | Spain | RCT | 96 | 66 (58-72)1 |
| Shelat *et al*[85] | 2015 | Singapore | Retrosp. | 22 | - |
| Shim *et al*[54] | 2018 | South Korea | Retrosp. | 22 | 65.5 ± 8.9 |
| Tabchouri *et al*[70] | 2018 | France | Retrosp. | 302 | 64.4 ± 11.1 |
| Tohme *et al*[55] | 2015 | United States | Retrosp., case-matched | 66 | 62.1 (11.2)1 |
| Topal *et al*[86] | 2012 | Belgium | Retrosp. | 81 | 64.3 (35.4-83) |
| Vibert *et al*[87] | 2006 | France | Retrosp. | 37 | - |
| Yue *et al*[39] | 2018 | China | Retrosp. | 78 | 74 (70-78) |
| Yun *et al*[88] | 2012 | South Korea | Retrosp. | 23 | - |
| Zeng *et al*[56] | 2016 | China | Retrosp., PSM | 79 | 69 (65-75) |
| Andorra *et al*[89] | 2013 | Spain | Retrosp. | 21 | - |
| Abu Hilal *et al*[90] | 2011 | United Kingdom | Retrosp., case-control | 21 | 64 (26-82) |
| Nomi *et al*[57] | 2015 | France | Retrosp., case-matched | 93 | 64 (32-85) |
| Topal *et al*[58] | 2013 | Belgium | Retrosp., case-matched | 20 | - |
| Vavra *et al*[63] | 2015 | Czech Republic, United Kingdom | Prosp., cohort | 25 | 62.1 ± 10.3 |
| Montalti *et al*[91] | 2016 | Belgium | Retrosp., PSM | 44 | - |
| Okuno *et al*[42] | 2018 | United States | Retrosp., PSM | 29 | 54 (27-78) |
| Portigliotti *et al*[92] | 2017 | France, Italy | Retrosp. | 78 | 62.3 (37.8-86.0) |
| Scuderi *et al*[93] | 2017 | Belgium, Norway, Italy, United Kingdom, Spain, France | Retrosp., PSM | 49 | - |
| Efanov *et al*[94] | 2020 | Russia | Retrosp. PSM | 51 | 59 (41-84) |
| Aghayan *et al*[47] | 2017 | Norway | Retrosp. | 296 | 66 (29-89) |
| Montalti *et al*[33] | 2015 | Belgium | Retrosp. | 114 | 66.4 ± 0.89 |
| Okumura *et al*[95] | 2019 | France | Retrosp., PSM | 82 | 65 (33-83) |
| Martínez-Cecilia *et al*[62] | 2018 | United Kingdom, Spain | Retrosp. | 21 | - |
| Berti *et al*[40] | 2015 | Germany | Retrosp. | 35 | 71 (35-82) |
| Dagher *et al*[61] | 2016 | United States | Retrosp., PSM | 89 | 66.6 ± 10.8 |
| Ferretti *et al*[64] | 2015 | France, United States, Italy, South Korea | Retrosp. | 142 | 66 (32-85) |
| Jung *et al*[96] | 2014 | South Korea | Retrosp., case-match | 24 | 60 (43-75) |
| Ratti *et al*[65] | 2016 | Italy | Retrosp., PSM | 25 | 60 (37-80) |
| Shin *et al*[34] | 2019 | South Korea | Retrosp., PSM | 109 | 56 ± 11 |
| van der Poel *et al*[97] | 2019 | The Netherlands, Belgium | Retrosp., PSM | 61 | 64 ± 13.1 |
| Xu *et al*[35] | 2018 | China | Retrosp. PSM | 20 | 58.2 ± 10.66 |
| Okumura *et al*[59] | 2019 | France | Retrosp., PSM | 38 | 62 (32-85) |
| Nomi *et al*[36] | 2016 | France | Retrosp. | 208 | - |
| Hallet *et al*[37] | 2017 | France | Retrosp,. PSM | 27 | 63.6 (59.0-70.9) |
| van der Poel *et al*[38] | 2019 | United Kingdom | Retrosp., PSM | 271 | 63 ± 11 |

1interquartile range.

Numbers are presented as median (range) or mean ± sD unless otherwise indicated. Prosp.: prospective; PSM: propensity score-matched; RCT: randomized controlled trial; Retrosp.: retrospective.

**Table 2 Study details of studies concerning prognostic factors**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Ref. | Year | Country | Study design | Specific for LLR? | Number of patients | Age in yr |
| Langella *et al*[52] | 2015 | Italy | Retrosp., case-control | No | 74 | - |
| Nomi *et al*[27] | 2016 | France, Japan | Retrosp., case-matched | Yes | 120 | 61 (26-89) |
| Postriganova *et al*[28] | 2014 | Norway | Retrosp. | Yes | 155 | 66 (35-84) |
| Tabchouri *et al*[70] | 2018 | France | Retrosp. | Yes | 302 | 64.4 ± 11.1 |
| Tohme *et al*[55] | 2015 | United States | Retrosp., case-matched | No | 132 | - |
| Topal *et al*[86] | 2012 | Belgium | Retrosp. | No | 274 | - |
| Yue *et al*[39] | 2018 | China | Retrosp. | Yes | 241 | - |
| Zeng *et al*[56] | 2016 | China | Retrosp., PSM | No | 158 | - |
| Montalti *et al*[33] | 2015 | Belgium | Retrosp. | Yes | 114 | 66.4 ± 0.89 |
| Cervantes *et al*[98] | 2019 | France | Retrosp. | Yes | 227 | - |
| De Haas *et al*[99] | 2009 | The Netherlands | Retrosp. | No | 796 | - |
| Jones *et al*[100] | 2014 | United Kingdom | Retrosp. cohort | No, only open | 73 | 69.1 (59.8-73.9)1 |
| Ratti *et al*[101] | 2019 | France, Italy | Retrosp., PSM | Yes | 146 | - |
| Nierop *et al*[102] | 2019 | The Netherlands, Belgium, United States | Retrosp. | No | 1302 | - |

1interquartile range.

Numbers are presented as median (range) or mean ± SD unless otherwise indicated. LLR: laparoscopic liver resection; PSM: propensity score-matched; Retrosp.: retrospective.

**Table 3 Operative outcomes**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Ref. | Blood loss (ml) | Operative time (min) | Intraoperative blood transfusion (%) | Conversion rate (%) | Major resection proportion (%) | R0 resection proportion (%) |
| LLR in general | | | | | | |
| Abu Hilal *et al*[24] | 300 (20-3000) | 220 (40-540) | - | 8 | - | - |
| Abu Hilal *et al*[71] | 363 (500)1 | 220 (145)1 | 2 | 12 | - | 96 |
| Allard *et al*[60] | - | - | - | 1.7 | - | 85.8 |
| Barkhatov *et al*[25] | 250 (0-4000) | 180 (41-488) | - | 1.4 | - | - |
| Beard *et al*[43] | - | - | - | - | - | 77.4 |
| Beppu *et al*[72] | - | 282 (60-1120) | 8.4 | - | 6 | 90 |
| Castaing *et al*[32] | - | 278 ± 123 | 15 | 10 | 43 | 87 |
| Chen *et al*[74] | - | - | - | - | - | 93.6 |
| Cheung *et al*[48] | 200 (10-1300) | 180 (58-460) | 0 | - | - | - |
| Cipriani *et al*[29] | 400 (10-2800) | 295 (10-540) | - | 9.8 | 48.9 | 92.5 |
| de’Angelis *et al*[44] | 200 (50-550) | 210.5 (60-420) | 5.8 | 5.8 | - | 82.7 |
| Efanov *et al*[77] | - | - | - | 3 | - | - |
| Fretland *et al*[9] | 300 (224 -375)2 | 123 (108-138)2 | - | 2 | - | - |
| Goumard *et al*[45] | 100 (10 - 805) | - | - | - | - | 81 |
| Guerron *et al*[50] | 376 ± 122 | 239 ± 17 | 5 | - | - | - |
| Inoue *et al*[80] | 99 ± 207 | 204 ± 101 | 4.3 | 4.2 | - | - |
| Iwahashi *et al*[81] | 198 ± 39 | 377 ± 29 | - | - | - | - |
| Karagkounis *et al*[46] | 200 (50-500)1 | 235 (185-307)1 | 4.6 | 7.7 | - | 78.5 |
| Kasai *et al*[82] | 50 (0-500) | 268 ± 104 | - | - | 18.2 | - |
| Kazaryan *et al*[26] | 300 (< 50-> 5000) | 192 (64-635) | 16 | 4.2 | - | 93.4 |
| Kubota *et al*[51] | 287.3 ± 459.3 | 333.9 ± 150.3 | 2.4 | - | - | - |
| Langella *et al*[52] | 100 ± 143.7 | - | 0 | - | 5.4 | - |
| Lewin *et al*[84] | - | - | - | - | 27 | - |
| Martínez-Cecilia *et al*[30] | 250 (10-2600)1 | 230 (30-555)1 | 11 | 7.6 | 21 | 88 |
| Nguyen *et al*[31] | 200 (20-2500) | 234 (60-555) | 10 | 3.1 | 45 | 94.4 |
| Nomi *et al*[27] | 200 (0-3000) | 245 (60-540) | 13.3 | 6.7 | 69.2 | 94.2 |
| Postriganova *et al*[28] | 250 (0-4000) | 152 (29-488) | - | 3.2 | - | - |
| Qiu *et al*[41] | 215 ± 170 | 235 ± 70 | - | 6.7 | - | - |
| Ratti *et al*[53] | 250 (100-900) | 220 (150-540) | 7.7 | 15.4 | 26.9 | - |
| Robles-Campos *et al*[49] | 100 (50-300)1 | 120 (90-180)1 | 4.2 | - | 11.5 | 95.8 |
| Shim *et al*[54] | 100 (30-950) | 135 (40-360) | 9.1 | - | 9.1 | - |
| Tabchouri *et al*[70] | - | - | - | - | 39 | - |
| Tohme *et al*[55] | 150 (50-150)1 | - | 12 | - | 23 | 88 |
| Topal *et al*[86] | 50 (10-300)1 | 120 (80-200)1 | - | - | 22 | - |
| Yue *et al*[39] | 260 (180-430) | 180 (160-260) | 5 | 7.7 | - | 78 |
| Zeng *et al*[56] | 250 (160-420) | 200 (150-230) | - | - | - | - |
| Major LLR | | | | | | |
| Abu Hilal *et al*[24] | 875 (75-3000) | 330 (180-540) | - | 19 | 33 | - |
| Abu Hilal *et al*[90] | 700 (75-3000) | 300 (180-465) | 22 | - | 100 | 95 |
| Nomi *et al*[57] | 300 (10-3000) | 274 (100-540) | 10.8 | 10.8 | 100 | 91.4 |
| Topal *et al*[58] | 550 (100-4000) | 257.5 (75-360) | - | - | 100 | 95 |
| Minor LLR | | | | | | |
| Abu Hilal *et al*[24] | 175 (20-1400) | 180 (40-340) | - | 4 | 33 | - |
| Vavra *et al*[63] | 132.3 ± 218 | 166.4 ± 81.5 | - | - | 0 | - |
| LLR of posterosuperior segments | | | | | | |
| Okuno *et al*[42] | 100 (10-800) | 217 (62-586) | 3.5 | - | 13.8 | 86.2 |
| Portigliotti *et al*[92] | 195 (0-1300) | 195 (40-600) | 1.2 | 2.5 | - | - |
| Efanov *et al*[94] | 282 (0-3300) | 327 (80-755) | - | - | - | - |
| Parenchyma sparing LLR | | | | | | |
| Aghayan *et al*[47] | 200 (< 50-4000) | 134 (20-373) | - | 1.7 | - | 81 |
| Montalti *et al*[33] | 250 (0-2800) | 276 ± 10.1 | - | 14.9 | 7 | - |
| Okumura *et al*[95] | 120 (0-2900) | 196 (20-480) | 2.4 | 3.7 | - | 96.3 |
| Simultaneous laparoscopic colorectal and liver resection | | | | | | |
| Berti *et al*[40] | 200 (70-1000) | 240 (120-450) | - | 0 | - | - |
| Dagher *et al*[61] | 229 ± 228 | 332 ± 110 | 8 | 7 | 8 | 90 |
| Ferretti *et al*[64] | 200 (0-1800) | 360 (120-690) | 8.5 | 4.9 | - | - |
| Jung *et al*[96] | 325 (50-900) | 290 (183-551) | - | 0 | - | - |
| Ratti *et al*[65] | 350 (100-1000) | 420 (170-720) | 8 | 4 | 24 | - |
| Shin *et al*[34] | - | 336 ± 119 | 13.8 | 2.8 | 29.4 | - |
| van der Poel *et al*[97] | 200 (100-700)1 | 206 (166-308)1 | - | 5 | 0 | 93 |
| Xu *et al*[35] | 175 (100-275) | 246.75 ± 78.20 | 20 | - | 20 | - |
| Two-stage hepatectomy | | | | | | |
| Okumura *et al*[59] FSH | 50 (0-350) | 159 (70-415) | 0 | 3 | - | 97 |
| SSH | 225 (50-1300) | 305 (150-480) | 13 | 11 | - | 95 |
| Repeat LLR | | | | | | |
| Nomi *et al*[36]  1st | 200 (10-3000) | 210 (40-540) | 9.9 | 4.3 | 46 | 93.6 |
| 2nd | 240 (10-1100) | 210 (90-600) | 2 | 0 | 42.6 | 97.9 |
| 3rd | 150 (10-600) | 250 (100-515) | 0 | 1.6 | 30 | 95 |
| Hallet *et al*[37] | - | 252.5 (180-322.5) | 14.8 | 3.7 | 92.6 | 84.6 |
| van der Poel *et al*[38] | 200 (50-600) | 193 (120-270) | - | 11.1 | 52.4 | 91.8 |

1interquartile range.

295% confidence interval.

Numbers are presented as median (range) or mean ± sD unless otherwise indicated. LLR: Laparoscopic liver resection.

**Table 4 Postoperative short-term outcomes**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Hospital stay (d)** | **Morbidity (%)** | **Major complications (%)** | **90-d mortality (%)** | **Time to AC (d)** |
| LLR in general | | | | |  |
| Abu Hilal *et al*[24] | 4 (1-15) | - | 11 | - | - |
| Abu Hilal *et al*[71] | 4 (2.5)1 | - | - | - | - |
| Allard *et al*[60] | 11.4 ± 10 | - | 17.6 | 2.3 | - |
| Beard *et al*[43] | 4 (2-6)1 | 27.8 | 14.8 | - | - |
| Beppu *et al*[72] | 12 (3-192) | 14.1 | - | 0 | - |
| Castaing *et al*[32] | 10 (5-50) | 27 | - | - | - |
| Cheung *et al*[48] | 4.5 (3-56) | 10 | 5 | - | - |
| Cipriani *et al*[29] | 4 (1-57) | 23.3 | - | 0.8 | - |
| de’Angelis *et al*[44] | 6 (2-13) | 17.3 | - | 0 | - |
| Efanov *et al*[77] | - | 15 | - | 0 | - |
| Eveno *et al*[78] | - | - | 17.9 | - | - |
| Fretland *et al*[12] | - | 19 | - | - | - |
| Fretland *et al*[9] | 2.2 (1.9-2.5)2 | 19 | - | 0 | - |
| Goumard *et al*[45] | 4 (1 - 12.5) | 26 | 14 | - | - |
| Guerron *et al*[50] | 3.7 ± 0.5 | 15 | 0 | - | - |
| Inoue *et al*[80] | 10.8 ± 11.2 | 8.7 | - | - | - |
| Karagkounis *et al*[46] | 4 (3-5)1 | 26.2 | 4.6 | - | - |
| Kasai *et al*[82] | 4 (2-15) | 15 | - | - | - |
| Kazaryan *et al*[26] | 3 (1-42) | - | - | - | - |
| Kubota *et al*[51] | 7.3 ± 1.8 | 2.4 | 0 | - | - |
| Langella *et al*[52] | 5 (3-13) | 13.5 | 2.7 | - | - |
| Martínez-Cecilia *et al*[30] | 5 (3-33) | 22 | 5 | 0.4 | - |
| Nguyen *et al*[31] | 4 (17-22) | 12 | - | - | - |
| Nomi *et al*[27] | - | 41.7 | 17.5 | 0.8 | - |
| Postriganova *et al*[28] | 3 (3-4) | 11 | 7.1 | - | - |
| Qiu *et al*[41] | 7.5 ± 1.5 | 26.2 | - | - | - |
| Ratti *et al*[53] | 3 (4-37) | 20.2 | 6.7 | 1 | - |
| Robles-Campos *et al*[49] | 4 (4-5)1 | 11.5 | 6.25 | - | - |
| Shim *et al*[54] | 8.5 (5-22) | 9.1 | 0 | - | - |
| Tabchouri *et al*[70] | - | - | - | 0.4 | - |
| Tohme *et al*[55] | 4 (3-6)1 | 26 | 6 | - | 42 (34-54)1 |
| Topal *et al*[86] | 5 (3-7)1 | 14 | - | - | - |
| Yue *et al*[39] | 10 (7-32) | 27 | 6.4 | 1.3 | - |
| Zeng *et al*[56] | 10 (8-25) | 17.7 | 2.5 | - | - |
| Major LLR | | | | |  |
| Abu Hilal *et al*[24] | 5 (2-12) | - | 19 | - | - |
| Abu Hilal *et al*[90] | 5 (3-20) | 14 | - | 0 | - |
| Nomi *et al*[57] | 10 (5-57) | 50.5 | 23.7 | 0 | - |
| Topal *et al*[58] | - | 35 | - | 0 | - |
| Minor LLR | | | | |  |
| Abu Hilal *et al*[24] | 3 (1-15) | - | 7 | - | - |
| Vavra *et al*[63] | 8.4 ± 2 | 4 | - | - | - |
| LLR of posterosuperior segments | | | | |  |
| Okuno *et al*[42] | 4 (1-12) | 20.7 | 10.3 | 0 | - |
| Portigliotti *et al*[92] | - | 35.5 | 13.5 | 0 | - |
| Efanov *et al*[94] | 9 (4-29) | - | - | 0 | - |
| Parenchyma sparing LLR | | | | |  |
| Aghayan *et al*[47] | 3 (1-35) | 14.5 | - | 0 | - |
| Montalti *et al*[33] | 6 ± 0.28 | 20.2 | - | - | - |
| Okumura *et al*[95] | 6 (1-45) | 11 | 6.1 | 0 | - |
| Simultaneous laparoscopic colorectal and liver resection | | | | |  |
| Berti *et al*[40] | 8 (4-30) | - | - | - | - |
| Dagher *et al*[61] | 10.3 ± 9.6 | 15 | 4 | 6 | - |
| Ferretti *et al*[64] | 8 (3-84) | 31 | - | 2.1 | - |
| Jung *et al*[96] | 8 (5-23) | 17 | 13 | - | - |
| Ratti *et al*[65] | 9 (4-17) | 24 | - | 0 | - |
| Shin *et al*[34] | 12 ± 6 | 20.2 | - | - | - |
| van der Poel *et al*[97] | 6 (5-9)1 | - | 15 | - | - |
| Xu *et al*[35] | 9 (8.25-11.75) | 15 | - | - | - |
| Two-stage hepatectomy | | | | |  |
| Okumura *et al*[59] | 6 (0-34) | 16 | 8 | 0 | - |
| FSH |
| SSH | 9 (4-49) | 26 | 18 | 3 | 1.4 mo (0.9-3.5 mo) |
| Repeat LLR | | | | |  |
| Nomi *et al*[36] | 7 (2-45) | 34.8 | 16.3 | 0.7 | - |
| 1st |
| 2nd | 7 (4-71) | 27.7 | 6.4 | 0 | - |
| 3rd | 9 (4-15) | 30 | 10 | 0 | - |
| Hallet *et al*[37] | 9 (8-18)1 | - | - | - | - |
| van der Poel *et al*[38] | 4 (3-7) | - | 7 | 0.7 | - |

1interquartile range.

295% confidence interval.

Numbers are presented as median (range) or mean ± SD unless otherwise indicated. AC: adjuvant chemotherapy; LLR: laparoscopic liver resection.

**Table 5 Long-term and oncologic outcomes**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Recurrence rate (%)** | **1-yr OS (%)** | **3-yr OS (%)** | **5-yr OS (%)** | **10-yr OS (%)** | **1-yr DFS (%)** | **3-yr DFS (%)** | **5-yr DFS (%)** | **1-yr RFS (%)** | **3-yr RFS (%)** | **5-yr RFS (%)** |
| LLR in general | | | | | | | | | | |  |
| Abu Hilal *et al*[71] | 16 (after median FU of 22 mo) | - | - | - | - | - | - | - | - | - | - |
| Allard *et al*[60] | - | - | 85 | 70 | - | - | 42 | 31 | - | - | - |
| Barkhatov *et al*[25] | - | - | - | 54 | - | - | - | - | - | - | - |
| Beard *et al*[43] | - | - | - | 60 | - | - | - | 44 | - | - | - |
| Beppu *et al*[72] | - | 96.3 | 84.2 | 70.1 | - | - | - | - | 70.7 | 54.5 | 53.4 |
| Berardi *et al*[73] | 56.9 (after median FU of 8.4 mo) | 94 | 74 | 54 | - | - | - | - | 66 | 46 | 37 |
| Castaing *et al*[32] | 57 (after median FU of 30 mo) | 97 | 82 | 64 | - | 70 | 47 | 35 | 65 | 30 | 30 |
| Cipriani *et al*[75] | 57.7 | 85.9 | 66.7 | - | - | - | - | - | 54.2 | 29.4 | - |
| Cipriani *et al*[29] | - | 90.8 | 76.8 | 64.3 | - | 68.5 | 44.1 | 35.8 | 60.5 | 30.4 | 23.7 |
| D’Hondt *et al*[76] | - | - | - | 65 | - | - | - | - | - | - | - |
| de’Angelis *et al*[44] | 44.2 (after mean FU of 58.6 ± 44.4 mo) | 96.1 | 80.7 | 73.1 | - | 75 | 28.8 | 21.1 | - | - | - |
| Eveno *et al*[78] | - | - | 71 | 70 | - | - | 34 | 27 | - | - | - |
| Guerron *et al*[50] | 35 (after median FU of 16 mo) | - | - | - | - | - | - | - | - | - | - |
| Hirokawa *et al*[79] | - | 100 | 88 | 88 | - | 61 | 41 | 41 | - | - | - |
| Iwahashi *et al*[81] | - | 100 | 84 | 42 | - | 57 | 14 | 14 | - | - | - |
| Karagkounis *et al*[46] | - | - | 76 | 62 | - | - | - | - | - | - | - |
| Kasai *et al*[82] | - | 100 | 85.4 | 68 | - | 55.7 | 30.4 | 30.4 | - | - | - |
| Kazaryan *et al*[26] | - | 84 | 69 | 47 | - | 63 | 45 | 42 | 44 | 24 | 24 |
| Kazaryan *et al*[83] | - | - | - | 46 | - | - | - | - | - | - | - |
| Kubota *et al*[51] | - | - | 88.4 | - | - | - | - | - | - | - | - |
| Langella *et al*[52] | 37.8 (after median FU of 35.7 ± 24.9 mo) | - | 91.8 | - | - | - | 69.1 | - | - | - | - |
| Lewin *et al*[84] | - | - | - | 54 | - | - | - | - | - | - | 36 |
| Martínez-Cecilia *et al*[30] | - | 93 | 68 | 43 | - | - | - | - | 71 | 43 | 31 |
| Nguyen *et al*[31] | - | 88 | 69 | 50 | - | 65 | 43 | 43 | - | - | - |
| Postriganova *et al*[28] | - | 84 | 64 | 49 | - | 61 | 45 | 41 | 48 | 35 | 33 |
| Postriganova *et al*[28] | 38.5 | - | - | - | - | - | - | - | - | - | - |
| Postriganova *et al*[28] | 67.7 (after median FU of 40 mo) | 92.5 | 71.5 | 49.3 | - | 72.7 | 33.5 | 22.7 | - | - | - |
| Postriganova *et al*[28] | - | - | - | - | - | 68.2 | 22.7 | 18.1 | - | - | - |
| Tabchouri *et al*[70] | 72 (after median FU of 16 mo) | - | 82 | 71 | 43 | - | - | - | - | - | - |
| Tohme *et al*[55] | - | - | 74.4 | 51.3 | - | - | - | - | - | - | - |
| Vibert *et al*[87] | - | 97 | 87 | - | - | 74 | 51 | - | - | - | - |
| Yue *et al*[39] | 52.5 (after FU of 31 mo) | - | - | 52 | - | - | - | 45 | - | - | - |
| Yun *et al*[88] | - | - | 95 | - | - | - | - | - | - | - | - |
| Andorra *et al*[89] | - | - | - | 43.5 | - | - | - | - | - | - | - |
| Major LLR | | | | | | | | | | |  |
| Nomi *et al*[57] | 67.7 (after median FU of 39 mo) | - | - | - | - | - | - | - | - | - | - |
| Topal *et al*[58] | - | 90 | - | 48 | - | 60 | - | 43 | - | - | - |
| Minor LLR | | | | | | | | | | |  |
| Vavra *et al*[63] | - | - | - | 82.1 | - | - | - | 63.2 | - | - | - |
| LLR of posterosuperior segments | | | | | | | | | | |  |
| Montalti *et al*[91] | - | 96.4 | 70.8 | 62.9 | - | - | - | - | 63.7 | 37.1 | 32.5 |
| Okuno *et al*[42] | - | 100 | - | - | - | - | - | - | 49.9 | - | - |
| Scuderi *et al*[93] | - | - | - | - | - | - | - | - | - | 36 | - |
| Efanov *et al*[94] | - | - | - | 60 | - | - | - | - | - | - | - |
| Parenchyma sparing LLR | | | | | | | | | | |  |
| Aghayan *et al*[47] | 64 (after median FU of 6 mo) | - | 68 | 48 | - | - | - | - | - | 36 | 34 |
| Montalti *et al*[33] | 57.9 (after mean follow-up of 30.9 mo ± 1.71) | 98 | 75 | 59 | - | - | - | - | 64.2 | 35.2 | 31 |
| Okumura *et al*[95] | 59.8 (after median FU of 33.9 mo) | - | 85.1 | - | - | - | - | - | - | 28.8 | - |
| Martínez-Cecilia *et al*[62] | - | 94 | 82 | 65 | - | - | - | - | 82 | 71 | 54 |
| Simultaneous laparoscopic colorectal and liver resection | | | | | | | | | | |  |
| Berti *et al*[40] | 60 (after median FU of 19 mo) | - | - | - | - | - | - | - | - | - | - |
| Dagher *et al*[61] | 28 (after median FU of 26 mo) | 97 | 78 | - | - | 79 | 64 | - | - | - | - |
| Ferretti *et al*[64] | 28.2 (after median FU of 29 mo) | 98.8 | 82.1 | 71.9 | - | 85.6 | 65.9 | 63 | - | - | - |
| Ratti *et al*[65] | 36 (after mean FU of 37 mo) | - | - | - | - | - | - | - | - | - | - |
| Shin *et al*[34] | - | - | 74.4 | - | - | - | 58.5 | - | - | 59.6 | - |
| Xu *et al*[35] | - | - | 51.3 | - | - | - | 31.6 | - | - | - | - |
| Two-stage hepatectomy | | | | | | | | | | |  |
| Okumura *et al*[59] | - | - | 80 | - | - | - | - | - | - | - | - |
| Repeat LLR | | | | | | | | | | |  |
| Nomi *et al*[36] | 77.8 (after a median FU of 43 mo) | - | - | 43.2 | - | - | - | - | - | - | - |
| Hallet *et al*[37] | 66.7 (after a median FU of 20.7 mo) | - | - | - | - | - | - | - | - | - | 21.4 |

DFS: disease-free survival; FU: Follow-up; LLR: Laparoscopic liver resection; OS: overall survival; RFS: recurrence-free survival.

**Table 6 General conclusions about laparoscopic liver resections**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ref. | Safe | Feasible | Effective | Oncological efficiency | Short-term advantages |
| LLR in general | | | | | |
| Abu Hilal *et al*[71] | Yes | - | Yes | - | - |
| Allard *et al*[60] | - | - | - | Yes | Yes |
| Beppu *et al*[72] | - | - | - | Yes | Yes |
| Castaing *et al*[32] | - | - | - | Yes | - |
| Cheung *et al*[48] | Yes | - | Yes | Yes | Yes |
| Cipriani *et al*[75] | Yes | - | - | Yes | Yes |
| Cipriani *et al*[29] | - | - | - | Yes | Yes |
| D’Hondt *et al*[76] | - | - | - | Yes | - |
| de’Angelis *et al*[44] | - | - | - | Yes | Yes |
| Eveno *et al*[78] | - | - | - | Yes | Yes |
| Fretland *et al*[12] | - | - | - | Yes | - |
| Guerron *et al*[50] | - | - | - | Yes | Yes |
| Inoue *et al*[80] | Yes | - | - | - | Yes |
| Iwahashi *et al*[81] | Yes | Yes | - | Yes | - |
| Karagkounis *et al*[46] | - | - | - | Yes | Yes |
| Kazaryan *et al*[83] | Yes | - | - | Yes | - |
| Kubota *et al*[51] | - | - | Yes | Yes | - |
| Langella *et al*[52] | Yes | - | - | Yes | - |
| Lewin *et al*[84] | - | - | - | Yes | - |
| Martínez-Cecilia *et al*[30] | - | - | - | Yes | Yes |
| Nguyen *et al*[31] | Yes | Yes | - | Yes | - |
| Nomi *et al*[27] | Yes | - | - | Yes | - |
| Qiu *et al*[41] | Yes | Yes | - | - | Yes |
| Ratti *et al*[53] | - | Yes | Yes | Yes | Yes |
| Robles-Campos *et al*[49] | - | - | - | Yes | Yes |
| Tabchouri *et al*[70] | - | - | - | Yes | - |
| Tohme *et al*[55] | - | - | - | - | Yes |
| Topal *et al*[86] | - | - | - | Yes | Yes |
| Yue *et al*[39] | - | - | - | Yes | - |
| Yun *et al*[88] | - | Yes | - | - | - |
| Zeng *et al*[56] | Yes | Yes | - | Yes | - |
| Major LLR | | | | | |
| Abu Hilal *et al*[90] | Yes | - | Yes | Yes | - |
| Nomi *et al*[57] | Yes | - | - | - | - |
| Topal *et al*[58] | - | Yes | - | Yes | - |
| Minor LLR | | | | | |
| Vavra *et al*[63] | - | - | Yes | Yes | - |
| LLR of posterosuperior segments | | | | | |
| Okuno *et al*[42] | - | - | - | - | Yes |
| Portigliotti *et al*[92] | - | - | - | - | Yes |
| Parenchyma sparing LLR | | | | | |
| Aghayan *et al*[47] | Yes | - | - | Yes | - |
| Montalti *et al*[33] | - | - | - | Yes | - |
| Okumura *et al*[95] | - | - | - | Yes | Yes |
| Simultaneous laparoscopic colorectal and liver resection | | | | | |
| Berti *et al*[40] | - | Yes | Yes | - | - |
| Dagher *et al*[61] | - | - | - | Yes | - |
| Ferretti *et al*[64] | Yes | Yes | - | Yes | - |
| Jung *et al*[96] | - | Yes | - | - | Yes |
| Ratti *et al*[65] | - | Yes | - | Yes | Yes |
| Shin *et al*[34] | - | - | - | Yes | Yes |
| van der Poel *et al*[97] | Yes | - | - | - | - |
| Xu *et al*[35] | Yes | Yes | Yes | - | Yes |
| Two-stage hepatectomy | | | | | |
| Okumura *et al*[59] | Yes | Yes | - | Yes | - |
| Repeat LLR | | | | | |
| Nomi *et al*[36] | Yes | Yes | - | - | - |
| Hallet *et al*[37] | Yes | Yes | - | - | - |
| van der Poel *et al*[38] | - | Yes | - | - | Yes |

LLR: laparoscopic liver resection.

**Table 7 Prognostic factors for survival in liver resection for colorectal liver metastases**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ref. | Prognostic factor | Affected outcome + influence | HR (95%CI) | *p* value |
| Langella *et al*[52] | Postoperative complications | Worse 3-yr OS | 3.804 (1.336-10.832) | 0.012 |
| Multiple metastases | 3.421 (1.317-8.890) | 0.012 |
| Nomi *et al*[27] | Synchronous CRLM | Worse OS | 1.482 (0.621-2.859) | 0.023 |
| Positive surgical margin | 2.342 (1.356-2.912) | 0.012 |
| Node-positive primary tumor | No difference in OS | 1.857 (0.712-3.459) | 0.382 |
| Bilobar metastases | 1.398 (0.728-2.458) | 0.298 |
| CRLM ≥ 5 cm | 6.813 (2.348-4.245) | 0.351 |
| Postriganova *et al*[28] | Resection margin width (< 1 mm, 1-< 3 mm, 3-< 10 mm and ≥ 10 mm) | No difference in length of survival | - | 0.988 |
| No difference in DFS | - | 0.978 |
| No difference in RFS | - | 0.913 |
| Tabchouri *et al*[70] | Node-positive primary tumor | Increased risk of recurrence | 1.611 (1.14-2.28) | 0.007 |
| Extrahepatic disease before hepatectomy | 1.745 (1.24-2.45) | 0.001 |
| R1 resection | 1.648 (1.08-2.52) | 0.021 |
| Age > 70 yr | Worse survival | 3.157 (1.10-3.10) | 0.021 |
| Recurrence | 4.637 (1.60-6.26) | 0.002 |
| Tohme *et al*[55] | MILS (*vs* OLR) | Timely initiation of AC | 2.23 (1.16-4.31) | 0.017 |
| OLR with postoperative complications (*vs* MILS without complications) | 0.45 (0.23-0.86) | 0.017 |
| Number of lesions (solitary *vs* multiple) | 1.71 (1.14-2.54) | 0.009 |
| Length of stay (> 4 *vs* ≤ 4 d) | 0.64 (0.41-0.99) | 0.043 |
| AC more than 60 d after surgery | Worse RFS |  | 0.05 |
| Worse OS | 0.06 |
| Topal *et al*[86] | Fong’s CRS | Worse DFS | 1.46 (1.19-1.78) | 0.0002 |
| Preoperative systemic chemotherapy | 1.70 (1.15-2.52) | 0.008 |
| Male sex | Worse OS | 2.54 (1.45-4.45) | 0.001 |
| Interval systemic chemotherapy and surgery for CRLM | 1.06 (1.01-1.10) | 0.012 |
| Fong’s CRS | 1.49 (1.16-1.91) | 0.002 |
| Yue *et al*[39] | TNM stage of primary tumor (III *vs* I-II) | Worse OS | 1.981 (1.258-3.854) | 0.021 |
| Disease-free interval (< 12 *vs* ≥ 12 mo) | 1.610 (1.378-2.873) | 0.015 |
| Number of metastases (≥3 *vs* < 3) | 1.500 (1.258-1.870) | 0.041 |
| Disease-free interval (< 12 *vs* ≥ 12 mo) | Worse DFS | 1.874 (1.215-2.001) | 0.036 |
| Preoperative CEA levels (≥ 5 *vs* < 5 ng/ml) | 1.740 (1.418-2.108) | 0.028 |
| Zeng *et al*[56] | Disease-free interval (< 36 *vs* ≥ 36 mo) | 5-yr OS | 2.9871 (2.012-6.980) | 0.009 |
| Disease-free interval (< 36 *vs* ≥ 36 mo) | 5-yr DFS | 2.9501 (1.895-3.562) | 0.010 |
| Montalti *et al*[33] | Lesions located in posterosuperior segments | Worse tumor recurrence | 2.4 (1.24-4.61) | 0.009 |
| Blood loss (≥ 1000 ml vs < 1000 ml) | 3.2 (1.23-7.99) | 0.012 |
| R1 margins | No difference in OS | 1.06 (0.57-3.80) | 0.37 |
| CEA levels (≥ 10 µg/l *vs* < 10 µg/l) | Worse OS | 4.2 (2.02-16.9) | 0.001 |
| Multiple lesions (>2 *vs* ≤2 lesions) | Increased risk of R1 margins | 9.32 (1.14-32.5) | 0.037 |
| Cervantes *et al*[98] | CRLM minimum size <9 mm | Worse RFS | 1.6 (1.1-2.4) | < 0.05 |
| Worse hepatic RFS | 1.8 (1.2-3.0) | < 0.05 |
| De Haas *et al*[99] | Development of adrenal metastases after LR | Worse survival | - | 0.020 |
| Jones *et al*[100] | SUVmean during PET-CT | Insignificant negative effect on OS | 1.053 (0.839-1.321) | 0.659 |
| Log(volume of tumor) | Insignificant negative effect on OS | 1.699 (0.964-2.993) | 0.067 |
| Ratti *et al*[101] | Right colonic neoplasms | Worse RFS | 2.382 (1.46-2.75) | 0.042 |
| T-stage of primary tumor (T3-T4) | 1.962 (1.55-3.01) | 0.044 |
| RAS mutation | 2.122 (1.33-2.96) | 0.039 |
| CRS > 3 | 2.572 (1.68-3.65) | 0.029 |
| Absence of perioperative chemotherapy | 2.312 (1.39-3.21) | 0.039 |
| Right colonic neoplasms | Worse OS | 2.412 (1.39-2.81) | 0.046 |
| T-stage of primary tumor (T3-T4) | 1.862 (1.43-2.78) | 0.048 |
| RAS mutation | 2.222 (1.42-3.07) | 0.037 |
| CRS > 3 | 2.752 (1.83-3.62) | 0.032 |
| Absence of perioperative chemotherapy | 2.162 (1.40-3.06) | 0.042 |
| Nierop *et al*[102] | Non-dHGP | Higher risk of positive resection margins | 1.7871 (1.112-2.871) | 0.016 |
| Number of CRLM | 1.1531 (1.077-1.234) | < 0.001 |
| Non-dHGP | Worse OS | 1.57 (1.26-1.95) | < 0.001 |
| Positive resection margins | 1.41(1.13-1.76) | 0.002 |
| Age at resection | 1.016 (1.008-1.023) | < 0.001 |
| Node positive primary | 1.455 (1.226-1.728) | < 0.001 |
| Number of CRLM | 1.078 (1.039-1.118) | < 0.001 |
| Size of CRLM | 1.063 (1.035-1.091) | < 0.001 |
| Preoperative CEA | No difference in OS | 1.000 (1.000-1.000) | 0.898 |

1odds ratio.

2risk ratio.

Numbers are presented as median (range) or mean ± sD unless otherwise indicated. AC: Adjuvant chemotherapy; CEA: Carcinoembryonic antigen; CI: Confidence interval; CRLM: Colorectal liver metastases; CRS: Clinical risk score; DFS: Disease-free survival; HR: Hazard ratio; LR: Liver resection; MILS: Minimally invasive surgery; non-dHGP: Non-desmoplastic growth pattern; OLR: Open liver resection; OS: Overall survival; PET-CT: Positron emission tomography-computed tomography; RFS: Recurrence-free survival; SUV: Standard uptake value.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**